Skip to main content

ACDD 2026 Extended Program

Page 1

Agenda Speakers Poster Session


2


Welcome to the 2026 Arizona Center for Drug Discovery + Development Summit This year’s summit, curated by the Arizona Center for Drug Discovery, will highlight translational research from bench to bedside and from creation to clinic, showcasing the discovery of effective drug candidates for cancer and the advancement of these innovative therapies into clinical trials. A key focus of the summit will be on fostering new partnerships and collaborations to accelerate the discovery, development, and commercialization of Arizona-based innovations.

Agenda Speakers Poster Session

3


AGENDA 8:00–8:30 AM REGISTRATION AND BREAKFAST WELCOME + INTRODUCTIONS 8:30–8:45 AM Dean Christopher Finch

R. Ken Coit College of Pharmacy University of Arizona

KEYNOTE 1

Dean Fred Wondisford

College of Medicine – Phoenix Campus University of Arizona

Julie Bauman, MD, MPH

8:45–9:25 AM “At the Frontier of Interdisciplinary Oncology in Arizona”

Chair +Professor, Interdisciplinary Oncology College of Medicine-Phoenix University of Arizona

“Exploiting NEDD8-Mediated Protein 9:25–9:55 AM Turnover: From Cancer Vulnerability to Clinical Translation”

Jennifer Carew, PhD

Professor of Medicine Chief, Division of Translational Medicine University of Arizona

Tim Marlowe, PhD 9:55–10:15 AM

“Focal Adhesion Therapeutics for Cancer & Fibrosis”

Associate Professor, Internal Medicine College of Medicine-Phoenix, University of Arizona Faknostics LLC

10:15–10:30 AM MORNING BREAK KEYNOTE 2 10:30–11:15 AM “(Re)inventing Drug Discovery with AI” 11:15–11:35 AM

Phil Tagari, PhD

Chief Scientific Officer, Insitro

“Building a Pipeline in a Pill with PMD- Sandi Dunn, PhD Founder and CEO of Phoenix Molecular Designs 026 a first in class pan-RSK inhibitor “ Phoenix Molecular Designs KEYNOTE 3

“How to Fix First-in-Human Trials 11:35–11:55 AM Now: Why America’s clinical on-ramp is stuck in the slow lane, and what it will take to unstick it” 11:55 AM–1:25 PM POSTER SESSION + LUNCH

Steve Potts, PhD, MBA Breakthru Medicine

Health Sciences Education Building (HSEB) - Lobby

Deepta Battacharya, PhD 1:25–1:55 PM

4

“Pluripotent Stem Cell Platforms for Regenerative Medicine.”

Inaugural Executive Director, Center for Advanced Molecular & Immunological Therapies (CAMI) Professor, Immunobiology University of Arizona


“RTX-117: A Transformative Therapy Paul August, PhD 1:55–2:25 PM for Charcot–Marie–Tooth Disease and CSO, ReviR Therapeutics Chair ACDD EAB Beyond” 2:25–2:45 PM

“Development of Selective Dyrk1a Inhibitors for Tauopathies”

Travis Dunckley, PhD

Co-Founder, Illuminos Therapeutics

Xinglong Wang, PhD Professor, R. Ken Coit College of Pharmacy “Targeting TDP-43: From Disease 2:45–3:05 PM R. Ken and Donna Coit Endowed Chair in Aging Mechanism to Therapeutic Discovery” and Neurodegenerative Diseases University of Arizona

“Is The Holy Grail of Cardiometabolic 3:05–3:25 PM Disease Attainable for Alzheimer’s and Dementia?”

3:25–4:05 PM

Roundtable Discussion: Beyond the Science – Building Investment Moderator: Leah Langlais, Tech Launch Arizona

Greg Thatcher, PhD

R. Ken and Donna Coit Endowed Chair in Drug Discovery Director, ACDD University of Arizona

Sandi Dunn, Phoenix Molecular Designs Mark Drew, Critical Path Institute (C-Path) Helen Goldstein, Procopio Caroline Walkinshaw, Exelle Bio

Dylan Peay, PhD 4:05–4:15 PM CLOSING REMARKS

4:15–5:30 PM

Manager of Workforce and Entrepreneurial Education Programs, AZAdvances and AZBio

CLOSING RECEPTION Sponsored by AZBio, AZAdvances, and VWR

Reception sponsored by:

5


8:30–8:40 AM

Welcome + Introductions Christopher K. Finch, PharmD, FCCM, FCCP Dean, R. Ken Coit College of Pharmacy University of Arizona

Christopher K. Finch, PharmD, FCCM, FCCP, became dean of the R. Ken Coit College of Pharmacy on August 1, 2026, succeeding interim dean Brian Erstad. Before joining the University of Arizona, he was Chair and Professor in the College of Pharmacy at the University of Tennessee Health Science Center (UTHSC), a college ranked sixteenth nationally and twelfth in NIH research funding. At UTHSC he coordinated and taught several courses, most recently developing a required course in health-system pharmacy outcomes and management. He earned his Doctor of Pharmacy from the University of Tennessee College of Pharmacy. Dr. Finch’s clinical interests include pulmonary disease, drug interactions, adverse drug events, and drug-induced disease. He has published more than 80 manuscripts in pharmacy and medical journals and has been an invited speaker at numerous national medical and pharmacy conferences. He is a Fellow of both the American College of Critical Care Medicine and the American College of Clinical Pharmacy, was named the Tennessee Pharmacists Association’s Tom C. Sharp Pharmacist of the Year in 2019, and joined the 2024 cohort of the University of Tennessee Executive Leadership Institute. As dean, he has said his priorities are to support the college’s people, strengthen its partnerships, and help the college make a meaningful impact across Arizona and the profession.

Fredric E. Wondisford, MD, MS, MBA Dean, College of Medicine – Phoenix University of Arizona

Fredric E. Wondisford, MD, MS, MBA, has been dean of the University of Arizona College of Medicine – Phoenix since October 2023. A physician-scientist with more than 30 years of experience in academic medicine and translational research, he developed, patented, and clinically launched Thyrogen®, a recombinant thyroid-stimulating hormone that changed the standard of care for patients with thyroid cancer. He has three patent applications pending for inventions related to diabetes and fatty liver disease, and his NIH-funded research has spanned thyroid disease, diabetes, and metabolic disorders. Before Arizona, he was Professor and Chair of the Department of Medicine at Rutgers Robert Wood Johnson Medical School, Henry Rutgers Chair and Chancellor Scholar at Rutgers Health, and Chief of the Medical Service at Robert Wood Johnson University Hospital. Earlier, he directed the Diabetes Institute at Johns Hopkins University, was Chief of the Endocrinology and Metabolism Division at the University of Chicago, and led the Thyroid Unit at Beth Israel Deaconess Medical Center and Harvard University. He completed his medical degree at the Northeastern Ohio College of Medicine, his internal medicine training at University Hospitals of Cleveland and Case Western Reserve, and an endocrinology research fellowship at the NIH, and earned MS and MBA degrees through a Cornell program in health care policy, management, and leadership.

6


8:45–9:25 AM

“At the Frontier of Interdisciplinary Oncology in Arizona” Julie Bauman, MD, MPH

Chair +Professor, Interdisciplinary Oncology College of Medicine-Phoenix University of Arizona

Julie E. Bauman, MD, MPH, is Professor and inaugural Chair of the Department of Interdisciplinary Oncology at the University of Arizona College of Medicine – Phoenix and Senior Medical Director of Oncology Research at Banner Health, a large integrated nonprofit health system headquartered in Phoenix. Previously, she was Dr. Cyrus Katzen Family Director of the George Washington University Cancer Center, Associate Dean of Cancer, and Professor of Medicine at the GW School of Medicine and Health Sciences. She received her MD and MPH from Tufts University in 1999, completed her internal medicine residency at the University of Utah, and trained in medical oncology at the University of Washington and Fred Hutch Cancer Center, where she was Chief Fellow. In 2011 she received the NCI Cancer Clinical Investigator Team Leadership Award. For two decades her research has centered on biomarkerdriven, early-phase clinical trials to prevent cancer or improve outcomes in tobacco-related cancers. She leads investigator-initiated, NCTN, and industry trials in head and neck cancer, including NRG-RTOG 1216, is Medical Director and MPI of the UA Cancer Prevention Clinical Trials Network, is Deputy PI and Chair of the Cancer Prevention Committee for the NRG NCORP Research Base, and has co-chaired the NCI Cancer Prevention Steering Committee for six years.

9:25–9:55 AM

“Exploiting NEDD8-Mediated Protein Turnover: From Cancer Vulnerability to Clinical Translation” Jennifer Carew, PhD

Professor of Medicine Chief, Division of Translational Medicine University of Arizona

Jennifer S. Carew, PhD, is Professor of Medicine at the University of Arizona College of Medicine – Tucson and Chief of the Department of Medicine’s reinstated Division of Translational Medicine, a role finalized in November 2025. She is also the University of Arizona Cancer Center’s Director of Translational Research, the college’s Director of Investigator-Initiated Clinical Trials, and Co-Director of the Cancer Center’s Hematological Malignancies Disease Team. Dr. Carew conducted her doctoral research at the University of Texas MD Anderson Cancer Center, studying the therapeutic implications of mitochondrial defects in chronic lymphocytic leukemia, and completed a postdoctoral fellowship at St. Jude Children’s Research Hospital, where she investigated strategies to overcome drug resistance in hematological malignancies. Her laboratory seeks selective therapeutic targets for patients with hematological malignancies, uses mechanistic approaches to study the safety, efficacy, and pharmacodynamics of experimental anticancer agents, and works with clinical collaborators to move discoveries into investigator-initiated early-phase trials. Her team is currently focused on essential regulators of protein turnover and epigenetic stability. Dr. Carew holds multiple patents and has received awards from the American Cancer Society, the Leukemia and Lymphoma Society, and the Voelcker Foundation, among others. She has hosted the Translational Medicine Symposium since 2024.

7


9:55–10:15 AM

“Focal Adhesion Therapeutics for Cancer & Fibrosis” Tim Marlowe, PhD

Associate Professor, Internal Medicine College of Medicine-Phoenix, University of Arizona Faknostics LLC

Timothy Marlowe, PhD, is an Associate Professor in the Department of Internal Medicine at the University of Arizona College of Medicine – Phoenix and Chief Scientific Officer of FAKnostics, LLC, a University of Arizona spin-out focused on focal adhesion kinase (FAK) diagnostics and therapeutics. He also directs the Molecular Discovery Core, which accelerates the discovery of drugs and chemical probes against multiple targets. Dr. Marlowe received his PhD in Molecular Pharmacology and Cancer Therapeutics from Roswell Park Cancer Institute and his BS in Pharmacology and Toxicology from the State University of New York at Buffalo. His expertise spans structure-based and computational drug design and a wide range of biophysical and biochemical assays, including surface plasmon resonance, NMR, and X-ray crystallography. His laboratory has identified a series of cyclic peptide-based drug candidates that inactivate the focal adhesion targeting (FAT) domain, the protein domain of FAK that regulates the focal adhesion complex and FAK localization. These promising molecules have shown significant efficacy in preclinical models of melanoma, liver fibrosis, and lung fibrosis and are in current pre-IND drug development studies. Dr. Marlowe’s FAKnostics is also one of the presenters at the White Hat Life Science Investor Conference.

10:30–11:15 AM KEYNOTE 2

“(Re)inventing Drug Discovery with AI” Phil Tagari, PhD

Chief Scientific Officer, Insitro

Philip Tagari is Chief Scientific Officer at insitro, a leading AI–drug discovery company. His team of multidisciplinary scientists and engineers is redefining disease biology and applying AI approaches to dramatically speed the delivery of meaningful therapeutics to patients with grievous disease. Before insitro, he spent more than a decade as Vice President of Research (Therapeutic Discovery) at Amgen Inc., where his global teams advanced over 30 innovative molecules into clinical development and commercialization, most recently including Imdelltra® (a first-inclass DLL3 BiTE®), Lumakras® (a first-in-class KRAS G12C inhibitor), MariTide (an anti-obesity bispecific), and Tezspire® (a first-in-class TSLP blocker). He is a Director of CQDM, the Quebec Consortium for Drug Discovery, and a Scientific Advisory Board member for BenchSci, a biology machine-learning company, and Orakl Oncology, a cancer AI predictive-modeling company. Before joining Amgen in 1998, Philip was a Research Fellow at Merck Frosst (Canada) Inc., where he contributed to the discovery of Singulair® and Vioxx®. He is a graduate of Gonville & Caius College, Cambridge University, and performed neurobiology research using pioneering quantitative image analysis at McGill and Oxford Universities.

8


11:15–11:35 PM

“Building a Pipeline in a Pill with PMD-026 a first in class pan-RSK inhibitor“ Sandi Dunn, PhD

Founder and CEO of Phoenix Molecular Designs Phoenix Molecular Designs

Sandra E. (Sandi) Dunn, PhD, is the founder and CEO of Phoenix Molecular Designs (PhoenixMD), a clinical-stage biotechnology company developing precise cancer therapeutics that target essential kinases. She founded the company in 2012 after functional genomic screens in her laboratory identified RSK as a prime target in triple-negative breast cancer (TNBC), the deadliest form of the disease. A breast cancer researcher for more than two decades, Dr. Dunn began her career as a postdoctoral fellow at the National Institutes of Health and has served on oversight committees including the Canadian Breast Cancer Foundation, the U.S. Department of Defense Breast Cancer Research Program, and the Susan G. Komen Foundation. PhoenixMD’s lead candidate, PMD-026, is a firstin-class, orally available RSK inhibitor designed for TNBC, developed with RSK2 as a biomarker for patient selection and a companion diagnostic created in collaboration with Roche. The FDA cleared its IND in 2019, and the Phase 1/1b trial dosed 41 patients at nine U.S. cancer centers; PMD-026 was well tolerated and could stop tumor growth for up to five months. The company plans to advance PMD-026 into Phase 2 combination trials for TNBC and hormone-positive breast cancer.

11:35–11:55 AM KEYNOTE 3

“How to Fix First-in-Human Trials Now: Why America’s clinical on-ramp is stuck in the slow lane, and what it will take to unstick it” Steve Potts, PhD, MBA Breakthru Medicine

Steve Potts, PhD, MBA, is the founding CEO of Breakthru Medicine, a preclinical-stage oncology company that emerged from stealth in January 2026 with a $60 million Series A. He has worked in oncology since 1999 across drug development and diagnostics, including medical affairs, clinical trials, product development, sales, marketing, and general management. He founded OncoMyx Therapeutics in 2018, raising $75 million in venture funding, and later served as CEO of SLAM Biotherapeutics. Earlier, as Vice President of Medical Affairs at Ignyta, which Roche acquired in 2017, he led the global testing of more than 20,000 patients in 15 countries in a basket trial of entrectinib, the first drug to receive breakthrough designation equivalents in the U.S., Europe, and Japan simultaneously. He also founded Flagship Biosciences, was General Manager for Life Sciences at Aperio, and built the bioinformatics department at Quest Diagnostics. He has raised more than $200 million for Arizona-based biomedical companies, sits on the AZBio Board of Directors, and chairs the Drug Development Council of the International Cancer Advocacy Network. In 2023 he testified before the U.S. Congress on the Inflation Reduction Act’s “small molecule penalty.” He holds a PhD and MBA from UC Davis and a BS in Physics from Wheaton College.

9


1:25–1:55 PM

“Pluripotent Stem Cell Platforms for Regenerative Medicine.” Deepta Battacharya, PhD

Inaugural Executive Director, Center for Advanced Molecular & Immunological Therapies (CAMI) Professor, Immunobiology University of Arizona

Deepta Bhattacharya, PhD, is the inaugural Executive Director of the University of Arizona Health Sciences Center for Advanced Molecular and Immunological Therapies (CAMI), a national biomedical research hub on the Phoenix Bioscience Core designed to bring together up to 40 principal-investigator groups. He is a professor in the Department of Immunobiology at the College of Medicine – Tucson, with an additional appointment in the Department of Surgery, and is a member of the University of Arizona Cancer Center and the BIO5 Institute. Dr. Bhattacharya joined the University of Arizona Health Sciences in 2017 from Washington University in St. Louis, where he was a professor of pathology and immunology. His research merges stem cell biology and immunology to understand lymphocyte development and to develop translational strategies against infectious disease, and he studies antibody responses to infections and vaccines. He was a New York Stem Cell Foundation Robertson Investigator in 2012, and his work has contributed to translational efforts at companies including Gilead Sciences, Sana Biotechnology, Clade Therapeutics, and Jasper Therapeutics. During the COVID-19 pandemic, his work on SARS-CoV-2 immunity with Dr. Janko Nikolich contributed to one of the world’s most accurate antibody tests, and he became a widely recognized science communicator. He is a former chair of the American Association of Immunologists’ Public Communications Committee.

1:55–2:25 PM

“RTX-117: A Transformative Therapy for Charcot–Marie–Tooth Disease and Beyond” Paul August, PhD

CSO, ReviR Therapeutics Chair ACDD EAB

Paul R. August, PhD, is Chief Scientific Officer of ReviR Therapeutics and chair of the ACDD EAB. A biotechnology executive with more than 25 years of experience, he has advanced small-molecule and RNA-targeted therapies from discovery through clinical development, with particular expertise in rare genetic and neurodegenerative diseases, including Charcot– Marie–Tooth disease (CMT), Huntington’s disease, and ALS. At ReviR he leads global research, translational medicine, regulatory strategy, and clinical development, and he has helped advance the company into the clinic, progressing RTX-117 into Phase 2 development, securing regulatory authorization for clinical studies in the United States and China, obtaining FDA IND clearance for CMT and vanishing white matter disease, and earning FDA Orphan Drug and Rare Pediatric Disease designations for CMT. Previously, he held senior scientific leadership roles at Agios, Icagen, and Sanofi, directing multidisciplinary programs from target discovery through candidate selection and clinical translation. He co-founded AcuraStem, whose ALS program AS-02 was acquired by Takeda in 2023. Dr. August earned his PhD from the University of Minnesota and has long been a driving force in building Southern Arizona’s bioscience ecosystem, including the BioSA Innovation Incubator.

10


2:25–2:45 PM

“Development of Selective Dyrk1a Inhibitors for Tauopathies” Travis Dunckley, PhD

Co-Founder, Illuminos Therapeutics

Travis Dunckley, PhD, is a neurogenomics and drug development researcher and co-founder of Iluminos Therapeutics, a biotechnology startup dedicated to developing novel diseasemodifying therapies across broad neurodegenerative tauopathies. Driven by a mission to combat age-related cognitive decline, his work bridges the gap between initial genomic discoveries and translational applications in medicine. Dr. Dunckley is a University of Arizona alumnus and has conducted research at the Arizona State University–Banner Neurodegenerative Disease Research Center, where he was an assistant research professor. He co-founded Iluminos with Christopher Hulme, a University of Arizona professor of medicinal chemistry, to advance small-molecule inhibitors of the kinase DYRK1A, an enzyme linked to the formation of the pathological tau and amyloid deposits associated with Alzheimer’s disease and to the cognitive deficits of Down syndrome. The compounds were designed and synthesized at the University of Arizona College of Pharmacy in collaboration with the Translational Genomics Research Institute, and were licensed to Iluminos through Tech Launch Arizona in 2017. In animal models, the compounds dramatically slowed the onset of Alzheimer’s disease pathology, and Iluminos has received a three-year, $3.5 million NIH Small Business Technology Transfer grant to support IND-enabling studies.

2:45–3:05 PM

“Targeting TDP-43: From Disease Mechanism to Therapeutic Discovery” Xinglong Wang, PhD

Professor, R. Ken Coit College of Pharmacy R. Ken and Donna Coit Endowed Chair in Aging and Neurodegenerative Diseases University of Arizona

Xinglong Wang, PhD, is the R. Ken and Donna Coit Endowed Chair in Aging and Neurodegenerative Diseases and Professor of Pharmacology and Toxicology at the University of Arizona. He received his PhD in Pathology from Case Western Reserve University in 2009. His laboratory investigates the molecular mechanisms underlying age-related neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, and amyotrophic lateral sclerosis (ALS), with a particular focus on TDP-43 proteinopathies and mitochondrial dysfunction. His lab provided the first evidence of TDP-43 accumulation within mitochondria in neurodegenerative diseases and suggested that targeting mitochondrial TDP-43 could be a novel therapeutic approach. His research combines mechanistic studies with therapeutic development to identify disease-driving pathways and translate these discoveries into potential treatments. In July 2026, Dr. Wang was senior author of a study in Nature Aging showing that blocking a small, highly conserved region of TDP-43 protected nerve cells in mice and in human nerve cells from the damage of ALS without disrupting the protein’s normal function. The team also tested an experimental compound, XL20, designed to bind that target region. His group is also working to identify small-molecule inhibitors of TDP-43 in mitochondria.

11


3:05–3:25 PM

“Is The Holy Grail of Cardiometabolic Disease Attainable for Alzheimer’s and Dementia?” Greg Thatcher, PhD

R. Ken and Donna Coit Endowed Chair in Drug Discovery Director, ACDD University of Arizona

Gregory R. J. Thatcher, PhD, is Professor of Pharmacology and Toxicology, holder of the R. Ken and Donna Coit Endowed Chair in Drug Discovery, and Director of the Arizona Center for Drug Discovery + Development at the University of Arizona. An accomplished medicinal chemist and pharmacologist, he joined Arizona in 2020 from the University of Illinois at Chicago (UIC), where he held the Hans W. Vahlteich Chair, founded and led the Translational Oncology Program of the University of Illinois Cancer Center, and in 2013 founded a campus-wide, disease-agnostic drug discovery center focused on small-molecule therapeutics. He earned his PhD at the University of Toronto and his BSc at the University of Manchester, and served on the chemistry faculty at Queen’s University in Canada from 1988 to 2002. In 1997 he created his first start-up, which took an Alzheimer’s drug into human clinical trials. His research has been continuously funded by the NIH since 2003, with more than 200 peer-reviewed publications and numerous patents, and spans estrogen-related breast cancer, epigenetic mechanisms of endocrine resistance, pancreatic cancer, and neurodegenerative disease. He has graduated 55 PhD students and is a dedicated mentor.

12


3:25–4:05 PM

Roundtable Discussion: Beyond the Science – Building Investment MODERATOR: Leah Langlais, Tech Launch Arizona Manager, Venture Development – Life Sciences, Tech Launch Arizona Drawing on more than 15 years of experience in business development, marketing, and corporate engagement, she helps transform University of Arizona discoveries into thriving life sciences ventures.

PANELISTS: Sandi Dunn, PhD

Founder and CEO of Phoenix Molecular Designs Phoenix Molecular Designs

Company builder, entrepreneur and inventor. Founder of Phoenix Molecular Designs a company with a pipeline in a pill that starts with breast cancer. Mark Drew Critical Path Institute (C-Path) 25+ years in biotech and pharma drug discovery and development with a focus on translational strategy, portfolio decision-making, and advancing academic innovations toward clinical development Helen Goldstein Procopio Corporate attorney advising life sciences companies from formation and financing through licensing, partnerships and M&A. Co-leads Procopio’s Life Sciences and Technology Transactions & Licensing practices. Caroline Walkinshaw Exelle Bio 25+ years in biopharma commercial strategy, portfolio decision-making and commercialization. Founder of Exelle Bio, working with biotech companies and academic innovators.

13


11:55 AM–1:25 PM

Poster Session

Awards to Top 3 Poster Presentations!

Sponsored by

www.azadvances.org

14


#1 - Katharine Johnson

PEAR1 is a Novel Regulator of intestinal Regeneration

PEAR1 is a Novel Regulator of Intestinal Regeneration Kate Johnson1,2,3, Julia Morris1,2,3, Curtis A. Thorne1,2 1 – University of Arizona, Department of Cellular and Molecular Medicine; 2 – University of Arizona Cancer Center; 3 – University of Arizona College of Medicine – Tucson

INTRODUCTION

RESULTS

A

3D Organoid Culture

96 (hrs)

B

Confluency Proliferation Phase

+ DSS Day 7

+ DSS Day 9

WT

WT

CONTROL

PEAR1 Nuclei

Figure 5 – A) PEAR1 increases throughout self-organization in mouse small intestine monolayers. B) Quantification of WT’s PEAR1+ cells at each timepoint (A).

50uM

B

PEAR1 decreases cell number and surface area coverage in late regeneration 04

A

24

48

96

72

(hrs) B

100 um

Patterned Monolayer Differentiation Phase

Figure 6 – A) Survival of WT and PEAR1 KO mice after acute colitis. Last day of DSS treatment (Day 7) indicated by arrow. Survival was significantly decreased in mice with PEAR1-KO (p=0.0033**). B) ) Colitis severity increases with DSS and is highest in PEAR1KO with DSS. PEAR1-KO mice without DSS exhibit low-grade colitis at baseline. Severity scores were assigned by a blinded veterinary pathologist. *P<0.05 by Welch’s t test C) Histology slides stained with hematoxylin & eosin of WT and PEAR1-KO mouse colons. PEAR1-KO + DSS exhibits severe inflammation with ulcerations; this damage is not resolved two days after DSS cessation (Day 9).

C

PEAR1-KO

Single Cells

C

A

2D Organoid Monolayer

Biopsy or Resection

H2B

72

WT

Single-Cell Dissociation

48

PEAR1-KO

Intestinal epithelium can be grown as organoids

24

PEAR1-KO

Wnt

B

A

Figure 1 – The intestine is lined by crypts with a stem cell niche located at the base. The epithelium is made up predominantly of colonocytes Differentiated with other rare, more specialized Transit-amplifying cells distributed throughout. This epithelial lining turns over every Stem 4 days. Opposing gradients of C morphogens like BMP (differentiation) and Wnt (stemness) regulate this turnover.

BMP

PEAR1-KO mice exhibit lower regenerative capacity

PEAR1 increases in intestinal monolayers throughout self-organization

Morphogens regulate intestinal epithelial turnover

100um 1000uM

Figure 2 – A) Intestinal epithelium harvested from patients during biopsy or mice after sacrifice can be dissociated and grown in an extracellular matrix (ECM) to form 3D organoids. These 3D organoids can again be dissociated and plated on a thin ECM layer to form monolayers, which recapitulate the organization of epithelial cell subtypes through a process termed self-organization. B) Self-organization involves 2 distinct phases. The proliferation phase is characterized by large-scale proliferation. During the differentiation phase, cells commit to terminal/ non-proliferative fates, stem cells form niches (white arrow), and proliferation is limited to the stem and transit-amplifying cell populations.

Figure 5 – A) WT and PEAR1-KO murine monolayers exhibit different morphologies during selforganization. Cell counts (B) and Surface area (C) quantified at each timepoint.

PEAR1 enhances sensitivity to BMP4 and attenuates response to Wnt3a WT

A

PEAR1-KO

0

0

Wnt3a (nM)

Regenerative genes were identified from RNA sequencing of damage-induced organoids

PEAR1

SUMMARY

1

1

Conclusions • •

5

5

• • •

Nuclei

Figure 3 – Through RNA sequencing of colonic organoids after mechanical damage on day 5 vs day 3 (A), and chemical damage via FOLFOX chemotherapy (B), we compared genes involved in both regenerative processes (C) and identified PEAR1 for further study.

Nuclei Edu Ki67

100um

B

•

1000uM

PEAR1 localizes to the differentiated cell compartment A

Future Directions

8

8 0

Nuclei PEAR1

B

5

9

BMP4 (nM)

0

5

9

C

• •

Utilize tissue-specific knockout of PEAR1 in mice for further exploration of regeneration after colitis Better define Wnt3a/ BMP4 interplay with PEAR1 mechanism and downstream mediators Replicate mouse experiments using human organoids with PEAR1 overexpression and knockdown

ACKNOWLEDGEMENTS Thorne Lab Curtis Thorne, PhD Pearl Wichaidit, PhD Marina Cardo Vila, PhD Reeba Varghese, PhD Julia Morris, PhD Crystal Morales, MS Briana Guzman Dylan Corcoran

100um

Figure 4 – A) Intestinal monolayers recapitulate 3D crypt structure. Edu marks stem cells and Ki67 indicates transit-amplifying cells surrounding the stem cell niche. B) Organoid monolayers from WT mouse small intestine reveal PEAR1+ cells in the differentiated zone.

HYPOTHESIS: PEAR1 potentiates BMP4-driven differentiation in late-stage intestinal regeneration.

PEAR1 upregulated in late-stage regeneration after damage PEAR1 is expressed the differentiated cell compartment in murine intestine and increases throughout self-organization Wnt3a decreases and BMP4 increases PEAR1 levels PEAR1 increases WT susceptibility to BMP4 signaling in terms of monolayer surface area coverage and CK20 intensity Knockout of PEAR1 leads to loss of crypt architecture, decreased survival, and reduced capacity for regeneration of intestinal lining in mice with DSS-induced colitis

Committee Jason Wertheim, MD, PhD Bruce Carter, PhD Kelvin Pond, PhD Curtis Thorne, PhD Collaborators Jayati Chakrabarti, PhD Mary Yagle, MS

Award Number: DK103126

Award Number: R35GM147128

Figure 7 – A) Full well images of nuclei (Dapi) in WT and PEAR1-KO monolayers across Wnt/BMP gradients. Loss of PEAR1 leads to increased monolayer surface area at baseline. PEAR1 sensitizes monolayers to BMP. B) Percent of PEAR1+ cells in WT monolayers across Wnt3a and BMP4 treatments. C) CK20 intensity across conditions. CK20 is a marker of differentiated cells. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

15


# 2 Sophie Mickelson, Manish Jain

Psychedelics Exhibit Polypharmacology and Reveal Multiple Targets for Potential Therapeutics

Psychedelics Exhibit Polypharmacology and Reveal Multiple Targets for Potential Therapeutics ★, and Manish K Jain1 Sophie Mickelson1★

Department of Translational Neurosciences1, College of Medicine - Phoenix, University of Arizona, Phoenix, AZ 85004, USA

Pairwise Tanimoto Similarity Scores Show Chemical Diversity

Pairwise Tanimoto similarity score heatmap for the selected 41 compounds.

Psychedelics Exhibit Polypharmacology Transduction coefficient

Ligands

Abstract Classical psychedelic drugs such as N,N′ -dimethyltryptamine (DMT), psilocybin, and mescaline have been used for millennia in Indigenous cultures for spiritual and medicinal purposes. Psychedelics produce a range of effects including hallucinations (visual, auditory, and tactile), changes in mood (euphoria, anxiety, and fear), ego dissolution, and a sense of profound interconnectedness. Recent clinical studies have suggested that classical psychedelics may have therapeutic potential for many neuropsychiatric conditions, including depression, anxiety, migraine and cluster headaches, drug abuse, and post-traumatic stress disorder. Classical psychedelics can be broadly categorized into three chemical classes: tryptamines, phenethylamines, and lysergamides. The prototypical psychedelics (+)-lysergic acid diethylamide (LSD), psilocybin, and mescaline exert their psychedelic effects via activation of the 5-HT2A serotonin receptor (5-HT2AR). In a recent study, Jain et al. (Neuron 2025) systematically investigated the pharmacology of 41 classical psychedelics from the tryptamine, phenethylamine, and lysergamide chemical classes. These compounds were profiled against 318 human G-protein-coupled receptors (GPCRs) to elucidate their target profiles using the PRESTO-Tango library. Selected interactions were subsequently validated using radioligand binding and functionally characterized using the TRUPATH assay for already known receptor-transducer pairs. This study reveals that psychedelics have potent and efficacious actions at nearly every serotonin, dopamine, and adrenergic receptor. Interestingly, the dopamine receptor family has high affinity for most of the lysergamides. Therefore, as a proof of concept, an activestate cryo-EM structure of D2R in complex with LSD was determined at 2.3 Å resolution. Collectively, these findings have provided a comprehensive dataset of the pharmacology of a large number of psychedelic molecules. The diverse signaling profiles of psychedelics observed across several GPCRs suggest the possibility that multiple receptor systems and signaling pathways contribute to the therapeutic effects of psychedelics.

GPCRome Screening using Presto-Tango Assay 41 compounds were screened against 318 GPCRs using PrestoTango assay.

Receptor-transducer pathways No activity Psychedelics are promiscuous in nature, activating serotonergic, dopaminergic, and adrenergic receptors across multiple G protein pathways.

Structural Insights into LSD Binding at D2R

Introduction ▪

Psychedelics produce profound, reversible changes in perception, cognition, and behavior and are associated with hallucinations.

▪

Psychedelics have shown clinical potential in the treatment of neuropsychiatric conditions including depression, anxiety, migraine, cluster headache, and drug abuse.

▪

Their mechanisms of action are not completely understood. However, they exert their effects via activation of 5-HT2A receptor.

▪

Classical psychedelics are broadly categorized into three classes based on their chemical structures: tryptamines, phenethylamines, and lysergamides.

▪

Here, we investigate the pharmacological profile of 41 psychedelic drugs against 318 GPCRs.

▪

Our results show that many biogenic amine GPCRs reveal a complex pharmacology that could be important for their therapeutic action in humans.

Raw Presto-Tango screening data for compounds screened at a single dose of 10, 3, or 1µM.

Selected 41 psychedelic ligands primarily activate serotonergic, dopaminergic, and adrenergic receptors.

Binding Affinity Heatmap

Model and map of LSD

D2R-LSD

Cryo-EM map of D2R-LSD at 2.3 Å D2R-LSD

5-HT2AR-LSD

Overlap of D2R-LSD and 5-HT2AR-LSD

5-HT2AR-LSD

As a proof of concept for the interaction of lysergamides with D2R, we solved the D2R-LSD cryo-EM structure.

Results

Conclusions and Future Directions

Psychedelic Ligands Selection and Pharmacological Profiling

• Classical psychedelics exhibit complex polypharmacology.

• Psychedelics exert their effects primarily by activating the serotonin 5-HT2A receptor. • Psychedelics also activate several other serotonin, dopamine, and adrenergic receptors, revealing multiple potential molecular targets for their actions. • All tested psychedelics activate the 5-HT2B receptor, which is associated with cardiac valvulopathy in humans. • Future directions involve the development of psychedelic-inspired G⍺q versus β-Arr2 biased nonhallucinogenic ligands. 255 psychoactive compounds with psychedelic-like actions in humans were clustered by structure, and 41 diverse compounds were selected for profiling through the pipeline shown.

16

Compounds that inhibited ≥50% in the single-dose screen were followed up with full concentration-response competition binding assays, and binding affinities (pKi) were plotted as a heatmap.

• Development of 5-HT2A-selective compounds over 5-HT2B to eliminate the risk of cardiac valvulopathy.


#3 Wenpan Li

TARGETING STANNIOCALCIN 1 TO BOOST IMMUNOGENIC TUMOR CELL DEATH AND CANCER IMMUNOTHERAPY

17


#4 Mengwen Li

Neddylation Blockade Potentiates Camptothecin Nanotherapy for Synergistic Topoisomerase I Inhibition in Advanced Colorectal Cancer

Strategic Integration of Saturated Phospholipids into Camptothesome to Enhance Colorectal Cancer Chemo-Immunotherapy Mengwen Li1, Wenpan Li1, Zhiren Wang1, Yanhao Jiang1, Elliott Shaw Brumbaugh1, Leyla Estrella Cordova1, Jianqin Lu1,2,3,4* 1 Skaggs Pharmaceutical Sciences Center, Department of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, The University of Arizona, Tucson, AZ, 85721, United States 2 Clinical and Translational Oncology Program, The University of Arizona Cancer Center, Tucson, AZ, 85721, United States 3 BIO5 Institute, The University of Arizona, Tucson, AZ, 85721, United States

4 Southwest Environmental Health Sciences Center, The University of Arizona, Tucson, 85721, United States

Abstract Colorectal cancer (CRC) remains largely refractory to immune checkpoint blockade (ICB), with clinical benefit limited to a small subset of immunogenic tumors, highlighting the need for more effective combination therapies. Although chemotherapy-induced immunogenic cell death (ICD) combined with immune modulation represents a promising strategy, its clinical translation is hindered by poor drug solubility, unfavorable pharmacokinetics, limited tumor delivery, and systemic toxicity. Here, we report a rational phospholipid engineering strategy to optimize our previously developed DOX-IND/Camptothesome platform by incorporating four FDA-approved phospholipids (DOPC, DSPC, HSPC, and SPC) at varying molar ratios to tune bilayer properties. Saturated phospholipids, particularly DSPC, significantly enhanced cellular uptake, IDO1 inhibition, ICD induction, T-cell proliferation, and tumor-targeted drug delivery. Consequently, the DSPC-engineered nanoformulation elicited superior antitumor efficacy and immune activation in advanced metastatic CRC models. Moreover, DSPC-fortified DOXIND/Camptothesome synergized with ICB to eradicate advanced immune-cold CRC tumors, establishing phospholipid membrane engineering as an effective strategy for enhancing chemo-immunotherapy and improving nanomedicine performance a clinically translatable strategy to enhance ICB responsiveness in CRC.

Optimizing the DOX-IND/Camptothesome with the addition of varied helper phospholipids

DOX-IND/Camptothesome containing 15% DSPC demonstrates superior therapeutic efficacy

Figure 1. Optimizing the DOX-IND/Camptothesome with the addition of varied helper phospholipids. (a) (b) (c) (d) Stability of DOXIND/Camptothesome/DOPC, DOX-IND/Camptothesome/DSPC, DOX-IND/Camptothesome/HSPC, DOX-IND/Camptothesome/SPC in 5% Dextrose under 4 °C for 7 days. Data are presented as mean ± SD (n = 3).

DSPC and HSPC fortified DOX-IND/Camptothesome enhances cellular uptake, cytotoxicity, IDO1 inhibition, and T cell proliferation

Figure 5. Investigating the therapeutic efficacy in the orthotopic MC38-Luc mouse model. DOX-IND/Camptothesome containing 15% DSPC demonstrates superior therapeutic efficacy compared with 5% Dextrose, unmodified DOX-IND/Camptothesome, and DOXIND/Camptothesome with 5% HSPC in the orthotopic MC38-Luc mouse model. IV injection was administered once on Day 10, when the tumor reached approximately 400 mg (n = 5 per group), at an eq. 14 mg CPT kg⁻¹. (20mg DOX-IND kg⁻¹.). (a) In vivo imaging of live mice on Days 10, 23, and 45 using the Lago imaging system. (b) On day 45, mice were sacrificed, and the heart, liver, spleen, lung, kidney, stomach, large intestine, small intestine, cecum, colon, and rectum were harvested for photography and ex vivo imaging. (c) Individual tumor growth curves were quantified based on total bioluminescence.

DOX-IND/Camptothesome plus dual ICB achieves advanced CRC tumor eradication

Figure 2. In vitro anticancer activity and immunology. DSPC and HSPC fortified DOX-IND/Camptothesome, cellular uptake, cytotoxicity, IDO1 inhibition, and T cell proliferation in cancer cells. (a) Representative flow histogram of DOX-IND/Camptothesome, DOXIND/Camptothesome with 20% DOPC, DOX-IND/Camptothesome with 15% DSPC, DOX-IND/Camptothesome with 5% HSPC, and DOXIND/Camptothesome with 25% SPC intracellular uptake at 4h in MC38 cell line . (b) Quantitative cellular uptake analyzed by GraphPad. (c) Cytotoxicity study of DOX-IND/Camptothesome nanoplatforms at 48h by MTT assay. (d) Surface expression of CRT using flow cytometry. (e) IL-6 level in MC38 cell evaluated using the IL-6 ELISA kit. (f) T cell proliferation by co-culture. Data in (b), (d), (e) and (f) are presented as mean ± SD (n = 3). Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparisons test.

Incorporation of DSPC and HSPC improved the safety profile of DOX-IND and CPT

Methods and Results Optimizing the DOX-IND/Camptothesome with the addition of varied helper phospholipids.

Figure 3. Determination of MTD. Incorporation of DSPC and HSPC increased the MTD of DOX-IND and CPT while avoiding systemic toxicity in healthy mice. (a-c) Weight changes and survival in healthy BALB/c mice. DOX-IND/Camptothesome formulations at various doses were administered intravenously to mice once via the tail vein. The body weight and survival were monitored for 2 weeks. Weight monitoring was terminated when there was more than 15% weight loss or mice death.

DSPC/HSPC enhances tumor accumulation and cargo co-localization

Figure 6. Testing the antitumor effects of combining the optimal CDL with ICB in late-stage orthotopic CT26-Luc mouse model. The combination of DOX-IND/Camptothesome + αPD-1+ αPD-L1 can eradicate advanced orthotopic tumors and prevent metastasis. Mice were inoculated with 1× 106 CT26-Luc cells into the caecum subserosa. On Day 12, mice (n = 5; tumors ~600 mg) were intravenously administered a single dose of 5% Dextrose, αPD-1+ αPD-L1, DOX-IND/Camptothesome, DOX-IND/Camptothesome with 15% DSPC, and DOX-IND/Camptothesome with 15% DSPC+ αPD-1+ αPD-L1 at the equivalent of 14 mg CPT kg-1and 20 mg DOX-IND kg-1. (a) Lago imaging of mice on Day 12, Day 15, Day 18, and Day 21. (b) Tumor growth curves were quantified based on total bioluminescence (n = 5). (c) Photography and ex vivo imaging on Day 21. (d) Representative immunohistochemical staining of tumor sections for CD91, TLR4, MHCΙ, IL-10 and CC3, scale bar 50 µm. (e)-(j) Quantification of IHC using ImageJ (n = 3). Data are presented as mean ± SD. Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparisons test.

Conclusion

In summary, rational phospholipid engineering optimized Camptothesome-based chemoimmunotherapy for colorectal cancer. Incorporation of 15% DSPC significantly improved formulation stability, tumor-targeted delivery, immunogenic cell death, IDO1 inhibition, antitumor immunity, and therapeutic efficacy. Combined with dual immune checkpoint blockade, the optimized formulation eradicated advanced orthotopic CRC and prevented metastasis, providing a clinically translatable strategy to enhance chemo-immunotherapy in immunologically cold colorectal cancer.

References Figure 4. Evaluating the biodistribution in the orthotopic32 MC38-Luc tumor model. In the orthotopic MC38-Luc tumor model, mice received a single intravenous injection of DOX-IND/Camptothesome formulations at a dose of 20/14 mg DOX-IND/CPT kg⁻¹. (a) Ex vivo imaging of tissue collected 24h after drug administration. Biodistribution of DOX and CPT fluorescence was assessed by Spectral Instruments Imaging Lago. (b)(c) Quantification of fluorescence intensity using Aura software. Data in (b) and (c) are presented as mean ± SD (n = 3). Statistical significance was determined by the two-tailed, unpaired Student’s t-test.

18

Funding

Li, M., Li, W., Wang, Z., Jiang, Y., … Lu, J. Nano Research, 2026. (In press)

1) R35GM147002 and R01CA272487. 2) Startup and Retention Funds from the R. Ken Coit College of Pharmacy. 3) PhRMA Foundation for Research Starter Grant in Drug Delivery. 4) UArizona Comprehensive Cancer Center (UACCC) Internal Pilot and Within Research Awards.


#5 Yanhao Jiang

Lipid Nanoparticle Co-Delivery of siRNA Silencing P-Glycoprotein Overcomes Camptothecin Resistance in an Acute Lymphoblastic Leukemia Model

Lipid Nanoparticle Co-Delivery of siRNA Silencing P-Glycoprotein Overcomes Camptothecin Resistance in an Acute Lymphoblastic Leukemia Model a, Karlie Elizabeth Fladera, Wenpan Lia, Mengwen Lia, Maxwell Maloneya, Mengjiao Maa, Hongmin Lia, Jianqin Lua,b,c,d* Yanhao ClickJiang to edit Master title style

a Skaggs Pharmaceutical Sciences Center, Department of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, The University of Arizona, Tucson, AZ, 85721, United States b Clinical and Translational Oncology Program, The University of Arizona Cancer Center, Tucson, AZ, 85721, United States c BIO5 Institute, The University of Arizona, Tucson, AZ, 85721, United States d Southwest Environmental Health Sciences Center, The University of Arizona, Tucson, 85721, United States

Introduction  P-glycoprotein (P-gp), encoded by ABCB1, is a major driver of multidrug resistance by actively exporting chemotherapeutics and reducing intracellular drug accumulation. This mechanism contributes to treatment failure in multiple cancers, including acute lymphoblastic leukemia (ALL). P-gp-overexpressing CEM/C1 cells therefore provide a useful model for studying resistance to camptothecin (CPT).  Strategies to overcome P-gp-mediated resistance include small-molecule inhibitors, nanocarriers, and gene silencing. siRNA can specifically suppress ABCB1 expression, potentially restoring drug sensitivity. Lipid nanoparticles (LNPs) protect siRNA from degradation and promote intracellular delivery, while ionizable lipids enhance endosomal escape. However, synchronized co-delivery of siRNA and chemotherapy remains challenging.  To address CPT resistance, we incorporated the ionizable lipid DLin-MC3DMA into the Camptothesome platform to develop siRNAP-gp/LNP-CPT. The formulation efficiently silenced P-gp, enhanced CPT retention, apoptosis, and cytotoxicity in resistant cells, and improved tumor accumulation and antitumor efficacy in vivo without overt toxicity, demonstrating a promising strategy for overcoming MDR.

Results and methods Schematic mechanism of action of siRNAP-gp/LNP-CPT

Silencing P-gp enhanced CPT cellular uptake in CPTresistant CEM/C1 ALL cells

Fig. 2. P-gp knockdown enhanced CPT uptake inside the CEM/C1 cells. (A) CPT fluorescence and differential interference contrast (DIC) imaging of various treatment groups in CEM/C1 cells. (B) Flow cytometry representative histogram (left panel) and quantitative data of CPT intensity in CEM/C1 cells. (C) Flow cytometry histogram of P-gp knockdown efficiency in CEM/C1 cells.

Co-delivery of siRNA targeting p-gp with LNP-CPT enhanced tumor delivery and drug retention

Co-delivery siRNAP-gp/LNP-CPT enhanced antitumor efficacy in an ALL-tumor model

Fig. 4. Co-delivery siRNAP-gp/LNP-CPT boosted antitumor efficacy in vivo. CEM/C1 ALL-bearing model was established by subcutaneous injection of 5 × 106 CEM/C1 cells. When tumors reached ~100 mm3 (Day 8), mice were intravenously injected with different formulations at eq. of 5 mg CPT/kg and 100 μg siRNA/kg on Days 9, 12, and 15 (n=5). (A) Tumor growth curve. (B) Individual mouse tumor growth curves. (C) Photographs of mice with tumors (white dashed circle) on Day 16. (D) Body weight monitoring.

Conclusion In summary, we developed a novel co-delivery lipid nanoparticle platform, siRNAP-gp/LNP-CPT, that co-encapsulates CPT and P-gp-targeting siRNA to effectively overcome multidrug resistance in acute lymphoblastic leukemia. By incorporating the clinically approved ionizable lipid DLin-MC3-DMA into our previously established phospholipid-derived CPT nanovesicle platform, we generated a stable nanocarrier with high siRNA encapsulation efficiency. In vitro, P-gp silencing markedly enhanced CPT uptake and retention, sensitizing CPT-resistant CEM/C1 cells to chemotherapy. In vivo, siRNAPgp/LNP-CPT achieved preferential tumor accumulation, prolonged intratumoral CPT retention, and superior antitumor efficacy without systemic toxicity. Mechanistic studies revealed that these therapeutic gains were driven by efficient P-gp knockdown, increased apoptosis, and enhanced DNA damage in tumors. Collectively, siRNAP-gp/LNP-CPT represents a promising nanotherapeutic strategy for reversing drug resistance and potentiating chemotherapy outcomes. Jiang, Y., Flader, K., Li, W., Li, M., Maloney, M., … & Lu, J. (2026). Acta Pharmaceutica Sinica B. DOI:10.1016/j.apsb.2026.07.052

Acknowledgments 1) NIH R35GM147002 and R01CA272487 2) PhRMA Foundation for Faculty Starter Grant in Drug Delivery 3) UArizona RKCCOP Startup and Retention Fund 4) UArizona Cancer Center (UACC) Internal Pilot and Within Reach Awards

Fig. 1. Development and proposed mechanism of siRNA-encapsulated sphingomyelin (SM)-derived CPT nanovesicle (siRNAP-gp/LNP-CPT). (A) Schematic mechanistic actions of siRNAP-gp/LNP-CPT inside the tumor cells. (B) siRNAP-gp/LNP-CPT is synthesized by ethanol injection technique, as previously published. Images created in https://BioRender.com.

Fig. 3. Augmented tumor delivery and retention of siRNAP-gp/LNP-CPT. (A) Mouse Lago optical imaging. (B) Representative ex vivo imaging of different. (C) ROI fluorescence intensity. (D) Blood kinetics for Cy5.5-siRNAP-gp, cy5.5-siRNAP-gp/LNP-CPT, and Cy5.5-siRNAP-gp/LNP + LNP/CPT. (E) The blood kinetics curve. (H) Ex vivo CPT fluorescence imaging. (I) Tumor accumulation of CPT (released CPT and SM-CPT) assessed by HPLC.

19


#6 Adrian De la Pena

MC1R LEAD OPTIMIZATION THROUGH PROTEIN COEVOLUTION AND BIOPHYSICAL ASSAY PIPELINE

MC1R LEAD OPTIMIZATION THROUGH PROTEIN COEVOLUTION AND BIOPHYSICAL ASSAY PIPELINE Adrian De la Peña1, Linnea Thim1, Kevin Scott2, Dr. Minying Cai1

References Department of Chemistry & Biochemistry, University of Arizona, Tucson, AZ 857211 College of Pharmacy, University of Arizona, Tucson, AZ 857212

Abstract Understanding GPCR activation is crucial for many physiological pathways. The complexity of not only pharmacological intervention at GPCRs, but also downstream effect specificity, makes GPCRs a promising but convoluted target for disease management. To help reveal functional motifs and “hotspots” in the melanocortin-1 receptor (MC1R), we used coevolutionary analysis of receptor orthologs. Coevolution finds residues that are pressured to mutate together over the course of evolution; these links have previously been found to indicate intra- or interprotein contacts. Combined with MMGBSA molecular docking, three experimental ligands (Melanotan-II, SHU9119, MSG606) were functionally analyzed. Coevolution models found links between residues in the binding pocket and the transducer interface of hMC1R and Gs-Protein/β-Arrestin1/β-Arrestin2. Docked and crystallized MC1R ligands exhibited interactions with orthosteric site residues that informed possible mechanisms of biased pathway choice by these functionally covariating residues. Experimental validation of biased agonism came from an optical assay for isolating binding events in real-time: plasmon waveguide resonance spectroscopy. This SPR-like assay can view real-time mass density changes in receptorembedded membrane systems that isolate transducer affinity differences across experimental MC1R ligands. This combined structure-activity relationship workflow has shown promise in unraveling the mechanism behind transducer bias at MC1R using receptor evolution. It is hoped that this can be universally applied as a novel approach to rationale-based drug design at any protein receptor.

Results

Introduction One way to tackle the structural basis of GPCR activity is through evolutionary analyses. Our novel approach, first proposed by Dr. Kevin Scott, uses the large databases of homologous proteins that are publicly available and analyzes covariation in residues across species. The idea of coevolution goes as far back as Charles Darwin, with the idea of individual residue coevolution being attributed to the covarion model [1] in the 1970s, and comparison of residue change across multiple sequence alignments (MSAs) in the 1990s [2]. On the level of proteins, a random point mutation in the sequence of a protein may cause a structural or functional defect that then has to be “counterbalanced” to keep the utility of that protein for sustaining the organism. Experimental detection of biased agonism was found using plasmon waveguide resonance spectroscopy (PWR). Developed originally at the University of Arizona [3], PWR can probe the surface of a metal-coated silica prism using laser light. The change in refraction index caused by mass density changes on the surface of the prism can give real time anisotropic data about binding events [4, 5]. We used isolated MC1R pretreated with a ligand in its native membrane and human GPCR transducers (Gs-Protein, β-Arrestin 1/2 [6]) together in PWR spectroscopy to measure binding affinity of each transducer for the MC1R-ligand complex. Combining structure-activity relationships from molecular docking, we can synthesize the coevolution and PWR data to elucidate more about the key structural aspects that dictate agonism, antagonism, and even biased signaling of MC1R.

A

MC1R/MTII

Figure 1: Covariation utility for drug design and furthering GPCR knowledge

B

A

100

Average Shift Incidence Angle (mdeg)

MSG606

ILE98

50

0

100

200

300

[Transducer] (nM)

-50

B

Figure 3: (A-C) Overlay of incidence angle shifting by transducer concentration in PWR spectroscopic assay by MC1R-ligand. The legend for each plot is shown below. (D) Schematic of PWR spectroscopy and theory. C

MC1R/SHU9119

100

MC1R F280

MC1R-MSG606 MC1R/MSG606

100

50

0

100

200

300

Average Shift Incidence Angle (mdeg)

Figure 2: Circos plot of covariating residues from the full hMC1R sequence without removing all MSA gaps

Average Shift Incidence Angle (mdeg)

Methodology

Known phosphorylation site

50

0

100

[Transducer] (nM)

200

[Transducer] (nM)

-50

-50

S316 P

βArrestin2

DD

300

Figure 4: (A) MSG606 (orange and grey ligand) docked to CryoEM structure of MC1R (Teal, PDB ID: 7F4D) overlaid with AlphaFold3 MC1R-βArrestin2 structure (dark blue). (B) Binding pocket of MC1R with green dotted lines showing hydrophobic interactions between MSG606 and residues of the crystal and AlphaFold structure (teal and dark blue, respectively). (C) Transducer interface between βArrestin2 and MC1R with polar noncovalent bonds shown as dotted lines.

R307

D403

C

Discussion

3. a) Run through coevolution software and FEL calculation [8] 1. Gather orthologs of the desired protein in an MSA [7]

2. Clean MSA for an accurate dataset by removing problematic residues/species

3. b) Generate AlphaFold Structure [9] for each sequence

4. b) Run through FrustraEvo [10]

Template ID: hypotheticalocean Size: 48x36

20

PWR revealed transducer bias for ligands of the MC1R (Figure 3). SHU9119 was found to favor Gs-Protein binding, MTII was balanced, and MSG606 favored β-Arrestin1. MTII is a known strong agonist at melanocortin receptors, while MSG606 is a novel antagonist at MC1R [11]. The decreased Gs-Protein binding in MSG606 further corroborates MSG606’s antagonist activity, while its arrestin bias could show that internalization of MC1R after MSG606 binding also contributes to antagonism at MC1R. A possible reason behind the difference in agonist bias could be that MTII conserves the full HFRW pharmacophore of melanocortin agonists, while SHU9119 has a D-Napthalene residues in the F position [12, 13]. Coevolution studies revealed a plethora of connections across the receptor (Figure 2). Many covariating residues seem inert, but others (Figure 4) could explain biased agonism and internalization of MC1R. MSG606 was seen to be the only docked ligand that interacted with F280, a coevolving residue of S316. This serine on the end of H8 is integral for receptor internalization [14], with BGM analysis showing unidirectional pressure on F280 from S316 mutations. Conformational changes enacted by pressure on F280 may be vital for GRK or arrestin binding for MC1R inactivation. Transducer interface residue R307, which establishes a H-bond with β-Arrestin2 in AlphaFold structures, was found to be coevolving with I98, another hydrophobic interaction that MSG606 makes. This could indicate another functional link to transducer bias. Evolution has been providing information about the optimal form of a protein for millions of years. Random mutations in protein structure across organisms are the implicit record of how a protein functions. Our coevolution method for protein characterization can be applied to any protein and is currently being used to optimize leads for drug discovery.

Acknowledgements I have the most gratitude for Dr. Kevin Scott for taking time from his extremely busy schedule to share this novel method for better understanding proteins. This would not have even existed without him. I thank the Undergraduate Biology Research Program and its funders, which allowed me to work on this project during the summer of 2025. I must also thank Linnea Thim for her help in working on the MC1R and Kyla Holmquist for her help in the lab. My last acknowledgement is for Dr. Cai, who manages the entire Cai Lab, which I have the great privilege to be a member of. She has helped guide this project and has been a most supportive mentor.


# 7 Julia Podgorski

ATAT1 Drives Pancreatic Cancer Initiation and Progression Through DNMT1 Stabilization and Epigenetic Silencing of Tumor Suppressors

ATAT1-Dependent Microtubule Acetylation Drives Pancreatic Tumorigenesis Through DNMT1-Mediated Regulation of NDRG4 Julia Podgorski1*, Paola Cruz Flores2*, Monique R. Archuleta1, Atsushi Ishii1, Aaron Ramonett1, and Nam Y. Lee1,2,3‡ 1Department of Pharmacology, University of Arizona, Tucson, AZ 85724, USA 2Department of Medicine, University of Arizona, Tucson, AZ 85724, USA 3Comprehensive Cancer Center, University of Arizona, Tucson, AZ 85724, USA

Abstract

Results

Microtubule (MT) acetylation is frequently elevated in cancer, yet whether specific tumors are selectively dependent on this modification remains unclear. Alpha-tubulin acetyltransferase 1 (ATAT1), the sole enzyme responsible for MT acetylation, has emerged as a potential therapeutic target, although the cancers most likely to depend on ATAT1 activity and the mechanisms through which it promotes malignancy also remain unknown. Here, using a phospho-specific marker of ATAT1 activity, we identify pancreatic ductal adenocarcinoma (PDAC) as an ATAT1-dependent malignancy. ATAT1 activity is elevated in human PDAC and genetically engineered mouse models, emerging during pancreatic intraepithelial neoplasia and persisting in a substantial subset of tumors. Genetic inactivation or pharmacologic inhibition of ATAT1 suppresses PDAC cell growth, reduces orthotopic tumor burden, and markedly inhibits tumor initiation in KPC mice without overt toxicity. Mechanistically, ATAT1-dependent MT acetylation sustains Akt signaling, resulting in inhibitory phosphorylation of GSK3β and stabilization of the DNA methyltransferase DNMT1. Elevated DNMT1 promotes repression of tumor suppressor genes, including NDRG4, whereas inhibition of ATAT1 or DNMT1 restores NDRG4 expression and impairs tumor growth. Together, these findings identify a previously unrecognized ATAT1-Akt-GSK3β-DNMT1 signaling axis linking cytoskeletal acetylation to NDRG4 repression and reveal ATAT1 as a therapeutic vulnerability during the earliest stages of pancreatic tumorigenesis.

ATAT1 Activation Specifically Enhanced in PDAC tumors

ATAT1 Activity Promotes DNMT1 Expression, Inhibits NDRG4 Expression

Introduction

ATAT1 Activity Promotes DNMT1 Expression, Inhibits NDRG4 Expression Links to disorders? Cell functions? Signaling?

What are the ATAT1-specific roles in cancer?

Results ATAT1 Activity Screen in Different Human Cancer Cell Types

Conclusion TGF-b TAK1 ATAT1 Microtubule Acetylation Rationale for ATAT1 Activity Screen - MT acetylation linked to cancer aggressiveness but mechanisms not fully understood - Elevated MT acetylation could reflect increased ATAT1 activity, reduced HDAC6/SIRT2 activity, or both - ATAT1 overexpression is rare in cancer, thus limiting expression-based profiling - P-S237-ATAT1 provides direct readout of ATAT1 activation, enabling activity-based screening across human cancers - This screen identifies cancers with selective ATAT1 hyperactivation and thus potential ATAT1-dependent therapeutic vulnerability

PDAC cell proliferation and progression - Promotes DNMT1dependent gene silencing of tumor suppressors such as NDRG4

Acknowledgements This work was supported by NIH grant R35GM148171, R01CA275036, and P30CA023074.

21


#8 Eric Dudebout

A Computational Pipeline for the de novo Design of Peptide Binders to SK Channels

22


#9 Yuan Xu

Local MD2 as a Peripheral Therapeutic Target for Inflammatory Pain: Evidence from Local Target Modulation and Electroacupuncture

Local MD2 as a Peripheral Therapeutic Target for Inflammatory Pain: Evidence from Local Target Modulation and Electroacupuncture Jiangjiang Fu2, Gangchen Cheng2, Zhongxi Lyu2, Zezhi Fan2, Feiyang Li2, Zhifang Xu2, Bo Chen2, Yongming Guo2, Yuhan Liu2, Hui Zhang2, Yi Guo2, Shengfeng Qiu1, Yuan Xu1,2 ¹ Basic Medical Sciences, College of Medicine – Phoenix, University of Arizona, Phoenix, AZ, USA; ² School of Acupuncture & Moxibustion and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin, China

Background

Results 1:Local MD2/TLR4/NF-κB signaling at ST36 is associated with analgesia effects of EA

⚫MD2, a key component of TLR4 signaling, is implicated in inflammatory and pain-related signaling.

A

⚫Whether MD2 at an accessible body-surface site can be directly modulated to regulate pain remains largely unexplored. ⚫Electro-acupuncture (EA) is a body-surface stimulation therapy with established analgesic effects, providing a paradigm to investigate local molecular mechanisms of pain relief.

Behavioral analgesia

MD2 (LY96) TLR4 co-receptor

+AIA

Local MD2/TLR4/NF-κB (p65) Expression at ST36 B

**P < 0.01 vs. the CON, ※※P < 0.01 vs. the SHAM.

⚫EA studies revealed activation of MD2/TLR4/NF-κB signaling at ST36 acupoint is associated with analgesia.

Results 2:Local MD2 manipulation functionally regulates analgesia

These findings raised the possibility that local MD2 itself may participate in pain regulation.

A

Behavioral analgesia

Local MD2/TLR4/NF-κB (p65) Expression at ST36 B

Central Question

Can local MD2 at an accessible body-surface site be directly targeted to modulate inflammatory pain?

*P < 0.05, **P < 0.01 vs. the AIA+OEcon.

Results 3:Local MD2 manipulation leads to molecular changes in spinal cord Spinal Proteomic Heatmap GO Enrichment Following Local Following Local MD2 MD2 Knockdown at ST36 Knockdown at ST36

Differential Proteins–Pathway Associations

Spinal GREM1, BMP4, and COX2 Changes Following Local MD2 Overexpression at ST36

Key message EA and local MD2 modulation (e.g., agonist) at ST36 may mimic the local MD2/TLR4/NF-κB (p65) signaling in fibroblasts, mast cells and macrophages within the acupoint connective tissue.

Targeting local MD2 at ST36 (e.g., agonist) may activate the same pathway, as EA.

This local signaling modulates spinal Grem1/BMP4/COX2 pathway and reduces PKC, CX3CL1 and IL-1β, ultimately producing analgesia.

Fu J, Cheng G, Lyu Z, et al. Front Immunol. 2026;16:1626755.

23


# 10 Keagan Neff

Investigating Monocyte Membrane-Coated Nanoparticle Delivery for Glioblastoma Using a 3D Engineered Tumor-on-aChip Model

24


# 11 Mehraneh Mohseni Zadeh Harouzi

Ruxolitinib Mitigates Xenogeneic GvHD and Spares Blinatumomab-Redirected Cytotoxicity In Vitro

Ruxolitinib Mitigates Xenogeneic GvHD and Spares Blinatumomab-Redirected Cytotoxicity In Vitro Mehraneh Mohseni1, Nina Santa Cruz2, Geovana Leite2, Dimitrios Filioglou3, Dan Davini2, Richard Simpson1,2,4,5, Emmanuel Katsanis1,2,3,5

1.University of Arizona Cancer Center; 2.Department of Pediatrics; 3.Department of Medicine;4.School of Nutritional Sciences and Wellness; 5.Department of Immunology, University of Arizona, Tucson, Arizona, USA

INTRODUCTION

RESULTS

• B-cell acute lymphoblastic leukemia (B-ALL) is the most common pediatric leukemia, and allogeneic hematopoietic cell transplantation (allo-HCT) can provide a curative graftversus-leukemia (GvL) effect. • Graft-versus-host disease (GvHD) remains a major cause of treatment failure and transplant-related mortality. • Current GvHD therapies often suppress antileukemic immunity, representing a key therapeutic challenge. • Ruxolitinib (Ruxo), a selective JAK1/2 inhibitor, attenuates immune activation by blocking STAT signaling. Blinatumomab (Blina), a CD3/CD19 bispecific T cell engager, redirects T cell–mediated cytotoxicity against B-ALL.

AIM • To uncouple GvHD suppression from GvL attenuation, enabling safer and more effective post-transplant immune modulation through rational combination therapy.

2A)

Figure 2: (A)Cell cytotoxicity. RS4;11 cells were co-cultured with PBMCs ± Ruxo and Blina for 24 hours. Blina mediated killing is largely preserved, with modest reduction at ≥1 µM Ruxo. Data are presented as mean ± SD (n=4)

1C)

1B)

CONCLUSIONS AND FUTURE DIRECTIONS

METHODS • Human peripheral blood mononuclear cells (PBMCs) were isolated using a Ficoll density gradient centrifugation and cocultured with RS4;11-Luc, (a CD19+ B-ALL cell line) in a 96 well plate for 24 hours in the presence and absence of Ruxo (0-8 µM) and/or Blina. • RS4;11-Luc cells were pre-labeled prior to co-culture; cytotoxicity was quantified by propidium iodide (PI) exclusion via flow cytometry. • For in vivo studies, NSG mice were engrafted with 10 x 106 PBMCs (Day 0) and treated with oral Ruxo (90mg/kg, Days 1-25) or vehicle control. GvHD severity was scored twice weekly using established clinical criteria. Weekly peripheral blood samples were collected via tail vein bleed and analyzed by flow cytometry to assess human leukocyte engraftment and T cell subset distribution. Mice were imaged twice weekly by bioluminescence imaging to monitor leukemia progression. 150cGy X-ray irradiation

End of treatment

1D)

1E)

End of treatment

Figure 1: (A) Representative bioluminescence images tracking tumor burden. Images are shown from one experiment at the indicated time points. (B) Quantification of bioluminescence signal over time. (C)GvHD scores. Parameters were assessed twice weekly. Mice that died were assigned a score of 8. (D) Survival analysis. Statistical comparisons were performed using the logrank test. Groups included: RS4;11-Luc alone(n= 12), PBMC alone (n=16), RS4;11Luc + PBMC (n=17) and RS4;11Luc+PBMC+Ruxo(n=17), RS4;11Luc+Ruxo (n=9). Data were pooled from three different experiments P*0.0309< 0.,**0.0072<0, ns=not significant. (E) Human cell engraftment in mice. The frequency of human CD45+ in the peripheral blood was assessed on day +7, +14, +21, +28

•Ruxolitinib significantly prolongs survival, attenuates clinical GvHD scores, maintains high engraftment, and allows for sustained low tumor burden in our xenogeneic mouse model •In Vitro, Blinatumomab preserves leukemia-specific cytotoxic activity in the presence of Ruxolitinibmediated T cell suppression, with only modest attenuation observed at the highest doses tested. •Together these findings support a combinatorial strategy to mitigate GvHD while maintaining antileukemic function, a critical step toward uncoupling these competing immune processes. •Ongoing in vivo experiments in xenogeneic B-ALL transplant models are directly testing whether this combination can effectively uncouple GvHD from GvL activity.

ACKNOWLEDGEMENTS This work was supported by Courtney’s Courage, PANDA NIH R01 CA277493 Simpson- Katsanis. Additionally, MMZH was supported by 22-1041992-01-DPBACC from the American Cancer Society. This research also was supported by the National Cancer Institute of the National Institutes of Health under award number P30CA023074 through the University of Arizona Comprehensive Cancer Center shared resources.

25


#12 Mozani Zianti

The therapeutic mechanisms of G-quadruplex binding compounds in Ewing Sarcoma

The Interplay of G-quadruplexes and R-loops in Ewing Sarcoma Cell Survival Ajibola D. Adelakun1,2,4, Mozani Zianti1, Chase Kappel3, Valery Thompson1, Haining Zhu3, Jacob C. Schwartz1,4 Click to edit Master title style

1 Department of Pharmacology, University of Arizona College of Medicine, Tucson AZ , 2 Department of Pharmaceutical Sciences, University of Arizona College of Pharmacy, Tucson, AZ,

3 Department of Pharmacology & Toxicology, University of Arizona College of Pharmacy, Tucson, Az, 4 University of Arizona Cancer Center, University of Arizona, Tucson AZ

Introduction and Background Maintaining genomic stability is fundamental for cellular health and disease prevention, particularly in the context of cancer. During transcription and replication, cells encounter various structural challenges within DNA and RNA. Notable among these are G-quadruplexes, fourstranded structures formed by guanine-rich sequences, and R-loops, which are RNA-DNA hybrids. These non-canonical structures pose significant obstacles to replication and transcription, frequently leading to genomic instability by creating conflicts between these vital cellular processes. The resolution of these complex nucleic acid structures is paramount to preserving genomic integrity. To explore the implications of these structures in drug discovery, researchers use Ewing sarcoma cell lines to test how candidate compounds affect tumor cell growth and survival. Drug screening evaluates a compound panel for antiproliferative activity, and promising hits are tested in combination, using a synergistic approach to see if paired agents outperform single drugs at lower doses. Effects are measured through relative cell count, viability assays, and cell cycle analysis by flow cytometry, which detects arrest or sub-G1 death. Together, these experiments can reveal novel therapeutic strategies for Ewing sarcoma and related diseases.

Results Figure 3: Viability test

Figure 4: Dose response: Ewing cells vs Non-Ewing cells

Methods Figure 2: Fluorescence-based Assay - G4-stabilizer screen Compounds were screened using a fluorescence melting assay. At the test temperature, G4DNA unfolds and fluoresces. A compound that stabilizes G4DNA keeps it folded, so the fluorescence stays quenched.

26

Discussion and Conclusion Our research illuminates the complex interactions between Gquadruplexes (G4s), R-loops, and specific helicases in maintaining genomic stability within cancer cells, showing that G-quadruplextargeting compounds inhibit Ewing sarcoma proliferation. We identified four compounds out of 30 that demonstrated significant effects on A673 cells, with enhanced efficacy in cells lacking the EWS::FLI1 fusion protein and found that G4 abundance and transcriptional addiction serve as predictive biomarkers of drug sensitivity. The EWS::FLI1-dependent response suggests a possible avenue for targeted Ewing sarcoma therapy. Further work will define the mechanism behind this selectivity. Our findings emphasize the importance of further investigating the specificity and effectiveness of G4-targeting compounds, laying the groundwork for future research aimed at leveraging these molecular interactions to develop novel therapeutic strategies in cancer and beyond.

Figure 1: Formation and resolution of G4s and R-loops. Mechanism of G4s and R-loop formation. Most R-loops form cotranscriptionally in cis when an mRNA transcribed by RNAPII reinvades and anneals to the template strand. RNAPII pausing at the 5′ end of genes can result in negative supercoiling which favous R-loop formation. The non-template, singlestranded component of R-loops can further fold into G-quadruplex structures (red), which can adopt either parallel or anti-parallel conformations with potentially distinct functions.

Figure 6: Cell Cycle Analysis

Figure 5: Relative cell count

Future Research Future PK/PD studies will be conducted to further characterize these findings

Funding This work was supported by the National Institutes of Health under grant CA259570 to J.C.S. and R01NS115507 to H.Z . Additionally, M.Z. was supported by 22-1041992-01-DPBACC from the American Cancer Society. This research also was supported by the National Cancer Institute of the National Institutes of Health under award number P30CA023074 through the University of Arizona Comprehensive Cancer Center shared resources, and the R Ken Coit endowment at the University of Arizona (to H.Z.).


#13 Reeba Varghese

Small Molecule Activation of Glycogen Synthase Kinase 3 Inhibits Wnt Signaling

Small Molecule Activation of Glycogen Synthase Kinase 3 Inhibits Wnt Signaling Reeba P. Varghese1,2, Marina Cardo Vila2,3, Pearl Wichaidit1,2, Briana Guzman1,2, Crystal Moales2,4, Curtis A. Thorne1,2 1Cellular and Molecular Medicine, 2University of Arizona Cancer Center, 3Department of Otolaryngology and Head & Neck Surgery, 4Cancer Biology GIDP, University of Arizona, Tucson, AZ

BACKGROUND Clinical Problem:

RESULTS- MOLECULAR MECHANISM OF ACTION Colorectal Cancer (CRC) is the 2nd leading cause

of death in men and women combined in the U.S. Majority of CRC cases have mutations in the Wnt pathway. However, there are no successful strategies to directly target the Wnt pathway.

GSK-3 is a key regulator of the Wnt Pathway GSK-3 plays a central role in multiple signaling pathways such as cellular proliferation where it acts as a negative regulator.

Mutations in upstream growth signals can inhibit GSK-3 kinase activity in CRC

A)

C)

Wnt-driven CRC and PDOs are sensitive to GA33 treatment

A)

B)

Figure 1: A) In vitro kinase assay of GSK-3 treated with GA33 shows a dose-dependent increase in kinase activity. B) Thermal stability assay of Human Colonic Epithelial Cells (HCECs) treated with 100µM GA33 at two different temperatures shows increased protein stability with GA33. C) Western blot detecting β-catenin following Wnt3a and GA33 treatment for 3 hours shows re-appearance of ubiquitin ladder expression (asterisk) with GA33 treatment despite Wnt stimulation. D) Immunofluorescence of HCECs treated with Wnt3a and GA33 for 24 hours, with quantification of images on the right, shows a dose-dependent decrease in β-catenin expression. Yaxis: Normalized nuclear β-catenin expression, Wnt-only = 100%, DMSO-only = 0%. Blue= Nuclei, Yellow= βcatenin, scale bar= 25um.

GA33 inhibits Wnt signaling at the destruction complex

Figure 2: A) Immunofluorescence of HCEC cells treated with Wnt or GA33 for 3 hours, with quantification on the right, shows a 2-fold increase in membrane-bound Wnt3a when treated with both, indicating a lack of receptor internalization. Blue= Nuclei, Green= Wnt3a, Yellow= β-catenin; scale bar= 25um.

Image adapted from Vogelstein et al.5

Hypothesis: Re-activating GSK-3 kinase activity using a small molecule can restore its function in conditions with low GSK-3 activity as observed in CRC

Combination of Biochemical and Cell-based assays identified a small molecule activator of GSK-3: GA33

B)

D)

A)

RESULTS- HIGH THROUGHPUT SCREEN

RESULTS- THERAPEUTIC POTENTIAL

GA33 enhances GSK-3 kinase activity and inhibits β-catenin

Figure 4: A) Viability of 4 CRC and HCEC cells treated with 0.1-100µM GA33 for 96 hours was measured using luminescence-based Cell Titer-Glo and showed that CRC cells with mutations in the Wnt pathway had decreased viability. B) Two patient-derived organoids (PDOs) that are Wnt-driven (Polyp, 451658) or not Wnt-driven (555926, 624824) were treated with GA33 for 10 days. Viability and organoid area were measured, showing that Wnt-driven PDOs had higher sensitivity to GA33. Viability was normalized to DMSO-only condition. Scale bar= 250um.

SUMMARY

B) B) Western blot of HCEC cells treated with Wnt or GA33 at different times shows that, with GA33, Axin1 protein is stabilized and LRP6 is not phosphorylated.

GA33 inhibits Wnt pathway transcription

Figure 3: RT-PCR quantification of the relative fold change in downstream Wnt target gene mRNA levels after 6 hours of treatment with Wnt and GA33 shows dose-dependent inhibition of the Wnt pathway. All normalized to DMSO-only condition.

• GSK3 is a central kinase involved in inhibiting proliferation and is regulated by upstream growth signals. • Mutations in CRC can constitutively suppress GSK3 activity. • We performed a large high-throughput screen and identified GA33, a smallmolecule activator. • GA33 enhances GSK-3 kinase activity, which increases β-catenin phosphorylation and Axin1 stabilization, resulting in decreased LRP6 phosphorylation and Wnt pathway inhibition. • GA33 treatment decreased Wnt-driven CRC and PDO viability. • This study shows that GSK-3 activation through a small molecule, GA33, can be a potential new CRC therapeutic strategy against Wnt-driven CRC.

REFERENCES 1Siegel, R.L. et al. Colorectal Cancer Statistics, 2026, CA: A Cancer Journal for Clinicians 2026, 76(2).

2Lieu, C.H. et al. Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer, Clinical Cancer

Research 2019, 25(19) 3Park, W.J and Kim. M.J. A new wave of targeting ‘undruggable’ Wnt signaling for cancer therapy: Challenges and Opportunities, Cells 2023, 12(8) 4Beurel, E et al. Glycogen Synthase Kinase-3: regulation, actions, and disease. Pharmacology & Therapeutics 2014. 5Vogelstein B, Papadopoulos N, et al. Cancer Genome Landscapes. Science 2013; 339: 1546-1558

ACKNOWLEDGEMENTS Research reported in this poster was supported by the NCI/NIH T32CA009213, NIH DK103126, NIGMS/NIH R35GM147128, Cockrum Innovation Award, and the UACC Pilot Funding. We would like to thank the Functional Genomics Core and the BioDRoid Core at UArizona and the High Throughput Screening Facility at the UT Southwestern University.

27


#14 Mengjiao Ma

Discovery and Preclinical Evaluation of Novel Brain-Penetrant Soluble Epoxide Hydrolase Inhibitors for Neuroinflammatory Diseases

Poster Number: 14

Discovery and Preclinical Evaluation of Novel Brain-Penetrant Soluble Epoxide Hydrolase Inhibitors for Neuroinflammatory Diseases Mengjiao Ma, Ke Chen, Yiding Huang, Anil Tharappel, Zhang Ran, Zhisong Gao, Rui Xiong, Zhong Li, Hongmin Li R. Ken Coit College of Pharmacy, Department of Pharmacology and Toxicology Results

N

TAMRA Background

Inhibitor

S/B Ratio

Comp

sEH

mp

sEH

X

Limited rotation High polarization

B

FP Binding Assay

Human Blood

C

CV

08 06 04 02 00

3

SH-SY5Y

B

Primary Astrocytes

IC50 = 15 nM Brain Penetration Following Oral Dosing

5. In Vivo Efficacy in LPS-Induced Parkinson’s Disease Model 6 3 Day 44 Day # #44

ck PS Mo L

TH

TH

Preclinical Evaluation

30 20 10 0

*** **

*

*

*

300 200 100 0

TH

Mock LPS #44 Day3 treat #44 Day6 treat

#44 Day 3

#44 Day 6

3 6 Day Day #44 #44

GAPDH

LPS

Rotarod test 400

Latency time (s)

Total descent time (s)

✓

Mock

Pole test 40

LPS

2.5

1.5

**

**** **

1.0 0.5 0.0

SNpc

GFAP

****

**** ***

2.0

Str

12 10

****

**** ****

**

ns

****

8

Mock LPS #44 Day3 treat

6

#44 Day6 treat

4 2 0

SNpc

SNpc

sEH

B Behavioral Tests

ck Mo

Str

Evaluate selected leads in an LPS-induced mouse model of PD

GFAP

D

TH

C

Merge

A Experimental Design

SNpc

Validate target inhibition, cellular activity, and brain penetration

3

20

CNS-penetrant leads

4. Cellular Anti-inflammatory Activity A

Brain Penetration (Oral)

GFAP

Lead Characterization

Potency & selectivity filters

Plate

GAPDH

2

54 compounds

Reorder & confirmed

10

2

504 compounds

CC50 > 500 μM

In h ib ito r

28

Z factor

4

3. Biochemical Activity and Brain Penetration A

Primary Hits Inhibition > 50%

100000

0

Free rotation Low polarization

Track plot

Identify novel sEH inhibitors using highthroughput screening

50000

PHOME Background

S/B Ratio

Screened using primary FP-based assay

Primary HTS

19

Str

Discovery

0

B Co

Inhibitor

4

2000

6

X

Overall Workflow 1

Neither

687

4000

0

Comp

9000 compounds

Both

B a c k g ro u n d

6000

SNpc

DHETs

O

High PHOME High TAMRA

# o f H ig h TA M R A

# o f H ig h P H O M E B a c k g ro u n d

8000

TH

sEH

O

N

C

TAMRA/PHOME Background

10000

Compound

Hypothesis Brain-penetrant sEH inhibitors will preserve endogenous EET signaling, suppress neuroinflammation, and protect the nigrostriatal dopaminergic system in Parkinson’s disease.

EETs

O

GFAP

1

Arachidonic acid

A Background in PHOME and TAMRA Channels

Compound

GFAP protein level ( Fold of Control)

•

Linker

TH protein level (Fold of Control)

•

Neuroinflammation is a common feature of many neurological disorders (e.g., Parkinson’s disease, Alzheimer’s disease, multiple sclerosis) and contributes to neuronal dysfunction and degeneration. Soluble epoxide hydrolase (sEH), encoded by EPHX2, hydrolyzes anti-inflammatory and neuroprotective EETs to less active DHETs. Preserving endogenous EET signaling through sEH inhibition may represent a therapeutic strategy for neuroinflammatory diseases.

(TAMRA)

CV, Z factor

Introduction •

2. From HTS to CNS-Penetrant Lead Compounds

1. Fluorescence Polarization-Based Binding Assay Carboxytetramethyl rhodamine

P0 P 87 0 P 088 P 089 P 090 P 91 0 P 092 P 093 P 094 P 095 P 096 P 097 P 98 0 P 199 P 100 P 101 P 102 P 103 P 104 P 05 1 P 106 P 107 P 108 P 09 1 P 110 P 111 P 12 1 P 113 P 114 15

Abstract Soluble epoxide hydrolase (sEH) has emerged as a promising therapeutic target for neuroinflammatory diseases because inhibition of sEH stabilizes endogenous epoxy fatty acids that exert potent anti-inflammatory and neuroprotective effects. The objective of this project is to discover and characterize novel brain-penetrant sEH inhibitors through an integrated drug discovery pipeline that spans high-throughput screening (HTS), lead identification, and preclinical validation. To achieve this, we established a fluorescence polarization-based HTS assay to identify novel sEH inhibitors from the chemically diverse compound library. Lead compounds were subsequently validated using orthogonal enzymatic assays, binding affinity measurements, structural characterization, and pharmacokinetic studies to confirm their potency and brain exposure. Functional evaluation in primary mouse astrocytes demonstrated that selected compounds significantly suppressed the expression of pro-inflammatory genes, supporting their anti-inflammatory activity. The lead compound was further evaluated in an LPS-induced mouse model of Parkinson's disease, where it reduced neuroinflammatory markers and preserved dopaminergic neurons. Collectively, this work establishes a comprehensive framework for the discovery and preclinical evaluation of brainpenetrant sEH inhibitors and supports the development of disease-modifying therapeutics for Parkinson's disease and other neuroinflammatory disorders.

Str

Conclusions

Future Directions

Acknowledgments

• A robust FP-based high-throughput screening platform enabled the discovery of novel sEH inhibitors. • Compound #44 emerged as a promising lead with potent sEH inhibition, favorable brain penetration, and anti-inflammatory activity in vitro and in vivo. • Brain-penetrant sEH inhibition represents a promising therapeutic strategy for neuroinflammatory diseases.

• Elucidate molecular mechanisms in primary CNS cells (e.g., NF-κB, EETdependent pathways). • Evaluate target engagement and downstream lipid signaling in brain tissue. • Assess efficacy in additional models of neuroinflammatory diseases (e.g., AD, MS). • Optimize lead compounds and evaluate long-term safety and efficacy.

We thank the Li Laboratory and collaborators for their support. This work was supported by the University of Arizona College of . Pharmacy and associated funding sources.


#15 Kai McAlister

5-HT2B Antagonism Reduces Renal Fibrosis and Improves Kidney Function in an Adenine-Induced Rat Model of Chronic Kidney Disease

29


#16 Aidan McMahon

DYR895: An orally bioavailable, brain penetrant, SMKI for simultaneous targeting of cancer growth and stemness

DYR895: An orally bioavailable, brain penetrant, SMKI for simultaneous targeting of cancer growth and stemness Aidan McMahon,1 Samantha Rokey,1 Alessandra Fistrovich,1 Timothy Chavez,1 Sean Ginn,1 Joaquina Nogales,2 Vasudha Tandon,2 Georgia Ferguson,2 Carly Cabel,3 Shravani Daptardar,3 Curtis Thorne,3,5,6 Sourav Banerjee,2,5,6 and Christopher Hulme 1,4,5,6 1 Department of Chemistry & Biochemistry, The University of Arizona, Tucson, AZ 85721 2 Division of Cancer Research, School of Medicine, University of Dundee, Scotland, UK 3 Department of Cellular and Molecular Medicine, The University of Arizona, Tucson, AZ 85721 4 College of Pharmacy, Medicinal Chemistry, The University of Arizona, Tucson, AZ 5 Iluminos Therapeutics LLC 6 Branch Therapeutics LLC Corresponding Authors: AidanMcMahon@arizona.edu, hulme@pharmacy.arizona.edu

Background Background

Pathways and Targets

Glioblastoma (GBM) and colorectal cancer (CRC) are aggressive malignancies with limited treatment options and poor patient outcomes. GBM is highly invasive and resistant to therapy, with median survival of only 12–15 months from diagnosis. CRC is the third most common cancer worldwide, with survival rates ranging from 91% for localized disease to 14% for distant metastases. Both cancers share features of high tumor heterogeneity, stemness, and plasticity, enabling resistance to standard monotherapies. The stemness-driven plasticity has been attributed to two main cancer stemness pathways – WNT-β-catenin and PI3K-AKTmTOR. Building on our selective DYRK1A inhibitor program, we developed a new series of pan-DYRK/CLK inhibitors designed to disrupt WNT signaling through both destabilization of the nuclear β-catenin complex and altered splicing of WNT target genes. This led to DYR726, a first-in-class compound that simultaneously inhibits PI3Kα, DYRK/CLK, higher-order CDKs, and type III receptor tyrosine kinases (PDGFR/KIT/FLT3), thereby targeting both mTOR and WNT pathways. DYR726 demonstrated superior potency against GBM and CRC in vitro compared to approved reference drugs, enhanced activity in combination with standard-ofcare and doubled survival rate in orthotopic and syngeneic glioma models. Optimization of this scaffold produced DYR895, an eight-fold more potent WNT inhibitor (EC50 = 5 nM) with minimal cytotoxicity in non-cancerous cells (HCEC GI50 = 6.5 µM). DYR895 is orally bioavailable, brain-penetrant with minimal efflux, and retains relative kinome selectivity despite its multi-target profile. It effectively killed primary patient-derived GBM cells and outperformed benchmark WNT inhibitors cirtuvivint and abemaciclib, demonstrating strong potential for clinical translation.

Competitive Landscape

Design and Synthetic Approach

Hinge Region

Conserved Lysine pocket

Cirtuvivint Pan-dyrk/clk inhibitor IC50 µM: 0.23-0.31 Suggested toxicity issues

Everolimus mTOR inhibitor IC50 µM: 1-20 Grade 4 toxicities exhibited

Temozolomide Alkylating agent IC50 µM: 10-500 50% patients exhibit resistance

 Current FDA treatment options exhibit:  Low IC50 values  Toxicity issues  Resistance to treatment  Low BBB penetrance

Solvent Exposed pocket

 Biological rationale for designing a targeted yet poly-pharmacologic small molecule kinase inhibitor. DYR726 and DYR895 have inhibitory activities against multiple kinases implicated in the Wnt/β-catenin and RTK signaling pathways.

• Simple, 4-5 step syntheses • Cost of goods anticipated to be low. • Readily scaleable routes to gram quantities.

Carmustine Chloro-ethylating agent IC50 µM: 28-300 Surgical implant (low BBB penetrance)

Bevacizumab Anti-VEGF mAb IC50 µM: 10-500 Second-round treatment option

Discovery of Current Lead Molecule: DYR895 DYR726 Profile:

Chemotype Evolution: Highly Potent WNT Inhibitor

DYR533 DYRK1A Selective S(35) selectivity score 0.027@1μM On critical path for IND-enabling studies (AD) (WNT EC50 17.74 uM)

DYR726 Pan-DYRK/CLK + GBM related-kinases S(35) selectivity score 0.1 @1μM GBM POC (WNT EC50 40 nM)

DYR895 Pan-DYRK/CLK + GBM related-kinases S(35) selectivity score 0.14 @1μM Current GBM Lead (WNT EC50 5 nM)

PDGFRa/b

PDGFRa/b PI3K

CDK7

DYRKs

RSK4 (false positive)

DYRKs/CLKs

PI3K CDK7/8/19

AKT1 (false positive)

DYR726 is a high affinity and functional inhibitor of PDGFRα/β

Multi-targeted (KDs/IC50) DYRK1A 0.37 nM PI3Kα 6 nM DYRK1B 6 nM PI3Kα E542K 4 nM DYRK2 2 nM PI3Kα E545K 5 nM DYRK3 11 nM PI3Kα H1047R 15 nM CLK1 2 nM PI3Kβ 2 µM CLK2 15 nM PI3Kγ 1 µM CLK3 137 nM BRAF 53 nM CDK7 8 nM BRAF (V600E) 75 nM CDK8 830 nM KIT 27 nM CDK19 3100 nM KIT (L576P) 9.8 nM PDGFRα 53 nM KIT (V599D) 10 nM PDGFRβ 48 nM AKT1 >10 µM WNT activity WNT reporter EC50 41 nM HCEC GI50 8.04 µM

Phys-chem Properties Molecular weight: 414 clogP 3.62 Log D 2.30 PSA 69.58 pKA 5.56 & 7.37 CNS MPO value 4.7 Surrogate PK data PAMPA 75.9 nm/s MLM T1/2 18.8 mins MLM T1/2 57.9 mins Kinetic solubility 68 µg/mL pH7 Mech. Based safety PDE3A IC50 18.2 µM (DYR533 2.61 µM)

DYR895 Profile: PK profile @25 mg/kg IP (female C57BL/6J mice) Cmax 3000 ng/mL T1/2 8 h KP ~ 1 Kpuu ~ 0.34 (excellent) Brain, fraction bound 97.1% Plasma protein binding 91.5% @10 mg/kg PO, 1 mg/kg IV (male CD-1 mice) F% 57%, T1/2 4 h (PO), T1/2 2.15 h (IV) Cmax ~100 ng/mL (PO) Suspected slow absorber

Efflux data MDR1 ER 3.2 BCRP ER 4.01

Multi-targeted (KDs) DYRK1A 0.29 nM CDK7 50 nM CDK8 44 nM CDK19 31 nM PDFRα 21 nM PI3Kα 10 nM

Phys-chem Properties Molecular weight: 473 clogP 3.73 PSA 78.81 pKA 6.34

Surrogate PK data PAMPA 75.9 nm/s WNT activity Kinetic solubility 61 µg/mL WNT reporter EC50 5.1 nM MLM T1/2 71.5 mins HCEC GI50 6.56 µM HLM T1/2 29 mins RLM T1/2 47 mins Mech. Based safety DLM T1/2 63 mins PDE3A IC50 1.95 µM CLM T1/2 12.3 mins (DYR533 2.61 µM) MNT positive Safety-based pharmacology: clean

PK profile @25 mg/kg IP (male CD-1 mice) Cmax 4893 ng/mL T1/2 2.45 h KP ~0.30 Kpuu ~ 1.59 Brain, fraction bound 80% Plasma protein binding 96.2% @10 mg/kg PO, 1 mg/kg IV (male CD-1 mice) F% 81%, T1/2 3.28 h (PO), T1/2 1.83 h (IV) Cmax 697 ng/mL (PO) Efflux data MDR1 ER 1.86 BCRP ER 2.59

DYR895 shows significant reduction in cell viability across various CRC cell lines

DYRKs/CLKs DYR726 ablates glioma progression through PI3K/WNT inhibition

Phospho-RTK array - inhibition of RYK

DYR726 PK and brain penetrance DYR726 is an isoform specific PI3Kα inhibitor

DYR895 shows significant reduction in cell viability 3-D organoid model

DYR726 reduces tumor burden in pilot TNBC syngraft

DYR726 improves mice survival in glioma model 3x weekly i.p. @ 50 mg/kg

DYR895 reduces tumor growth and improves survival of HCT-116 mice Thorne HCT-116 with DYR895 Survival Graph

100 90

Control

80 70 60

DYR895

% Alive

50 40

5x weekly i.p. @ 25 mg/kg

30 20 10 0

Conclusion and Future Directions  Our work has afforded lead molecule, DYR895, which displays a unique multi-targeted nature with key cancer stemness drivers of GBM  PI3K/AKT/mTOR; WNT; PDGFRα  Safe, orally bioavailable, and highly brain penetrant  Well-tolerated (MTD >50 mg/kg); F% 81; Kp,uu 1.59

30

 Explore SPR to improve poor human microsomal stability of DYR895  Current GBM in vivo study underway for DYR895  Additional indications: Alzheimer’s Disease, TNBC, liver, and ALS  DYR726 and DYR895 available through MTA

References Cuddapah VA, Robel S, Watkins S, Sontheimer H. A neurocentric perspective on glioma invasion. Nat Rev Neurosci. 2014;15(7):455-65. Pearson, J., Regad, T. Targeting cellular pathways in glioblastoma multiforme. Sig Transduct Target Ther 2, 17040 (2017). Latour M, Her N-G, Kesari S, Nurmemmedov E. WNT Signaling as a Therapeutic Target for Glioblastoma. International Journal of Molecular Sciences. 2021; 22(16):8428. Boni J, Rubio-Perez C, López-Bigas N, Fillat C, de la Luna S. The DYRK Family of Kinases in Cancer: Molecular Functions and Therapeutic Opportunities Cancers (Basel). 2020; 12(8): 2106. Siegel, R. L.; Miller, K. D.; Goding Sauer, A.; Fedewa, S. A.; Butterly, L. F.; Anderson, J. C.; Cercek, A.; Smith, R. A.; Jemal, A. Colorectal Cancer Statistics, 2020. CA Cancer J Clin 2020, 70 (3), 145–164. Zhan, T.; Rindtorff, N.; Boutros, M. Wnt Signaling in Cancer. Nature Publishing Group 2017, No. July 2016, 1461–1473. Kahn, M. Can We Safely Target the WNT. Nature Publishing Group 2014, 13 (7), 513–532. Tam, B. Y.; Chiu, K.; Chung, H.; Bossard, C.; Nguyen, J. D.; Creger, E.; Eastman, B. W.; Mak, C. C.; Ibanez, M.; Ghias, A.; Cahiwat, J.; Do, L.; Cho, S.; Nguyen, J.; Deshmukh, V.; Stewart, J.; Chen, C. W.; Barroga, C.; Dellamary, L.; KC, S. K.; Phalen, T. J.; Hood, J.; Cha, S.; Yazici, Y. The CLK Inhibitor SM08502 Induces Anti-Tumor Activity and Reduces Wnt Pathway Gene Expression in Gastrointestinal Cancer Models. Cancer Lett 2020, 473, 186–197. Foley, C., Hulme, C. “Small Molecule Inhibitors of DYRK/CLK and Uses Thereof” U.S. Patent WO 2022/0041590 A1, Feb. 10, 2022. Fistrovich, A., Shaw, Y., Chavez, T., Tandon, V., Banerjee, S., Hulme, C. “Small Molecule Inhibitors of DYRK/CLK and Uses Thereof” U.S. Patent WO 2023/250082 A2, Dec. 28, 2023.

0

10

20

30

40

50

Acknowledgements NIA GN (1R01NS109422-01A1) CPath TRxA Grant Alzheimer’s Drug Discovery Foundation GN (2013749) NINDS (R42, SBIR/STTR to Iluminos Therapeutics LLC)

60


#17 Hunter O’Brien

FAK FAT Inhibition Attenuates ITGA3 Mediated Survival Signaling in ITGA3-High Melanoma

FAK FAT Inhibition Attenuates ITGA3 Mediated Survival Signaling In ITGA3-high Melanoma Hunter O’Brien1; Wazir Abdullahi, Ph.D. 1; Lauren Reyes1; Timothy Marlowe, Ph.D. 1

1Department of Internal Medicine, College of Medicine-Phoenix, University of Arizona

Introduction

Melanoma in The Population

• Skin Cancer is the most fifth common cancer in the United States.1 • While only 1% of skin cancer cases, melanoma accounts for 80% of skin cancer deaths.1 • A 320% increase in melanoma incidence was seen in the US from 1975-2018.1 • Metastatic melanoma has a five-year survival rate of only 29.8%1, despite the widespread use of targeted therapies and immune checkpoint inhibitors.

FAK and FAK Targeting Therapeutics

Results

Depmap demonstrates relationship between FAK sensitivity and ITGA3 expression

ITGA3 High Melanoma Cells are Sensitive to FAK FAT Inhibition

• Depmap analysis of protein expression and FAK knockdown sensitivity identified ITGA3 to have a significant correlation across all surveyed cancer cell lines (R=-0.386, p-value= 3.64x10-39). • Knockdown of FAK, as well as focal adhesion proteins, Paxillin, Talin1, and Vinculin saw similar correlations with ITGA3 expression in melanoma.

• CTG viability assays determined that ITGA3 high cell lines had a significantly higher response to FAK-FAT domain targeting therapeutics. UA-2012 (p-value: 0.0156) and FRNK (p-value: <0.0001). • Conversely, there were minimal differences in FAK kinase targeting therapeutics Defactinib (p-value: 0.2638).

• FAK has been a prominent melanoma target since its discovery over 30 years ago.2 • FAK kinase inhibitors, like defactinib, have seen limited efficacy and selectivity in patients. • The Focal Adhesion Targeting domain (FAT) of FAK has emerged as a promising new target for FAK dependent cancers. • UA-2012, a novel peptide inhibitor, serves to disrupt FAK-FAT signaling. • FAK expression itself has not been predictive of FAK inhibitor treatment efficacy.

Integrins and “Outside-In” Signaling

• Integrins are transmembrane, heterodimeric, molecules that signal from the ECM inward to the cell through the FAK-FAT cascade.3 • These signals result in cell survival, proliferation, migration and anoikis resistance.3 • Integrin expression being predictive of FAK inhibitor efficacy is promising, however currently not well understood.

Figure 3. Depmap demonstrates relationship between FAK sensitivity and ITGA3 expression: Depmap correlations showing ITGA3 mRNA expression versus the effect of CRISPR deletion of crucial focal adhesion genes on cell survival (gene effect) in both all cancers and in melanoma.

Melanoma cells show differences in ITGA3/ITGB1, but not major focal adhesion proteins

Figure 1. “Outside-In” Integrin Mediated FAK-FAT Signaling: Graphic displaying key members of signaling from the ECM, through integrins, to FAK. Created in BioRender.com

• A small cohort of ITGA3 high and low were identified, creating the melanoma cell line panel. • The melanoma cell line panel saw no significant variance in expression of focal adhesion proteins TLN-1, FAK, or PXN. • A significant difference was seen in both ITGA3 (p-value: 0.0002) and ITBG1 (p-value: <0.0001) expression. ITGA3-high

ITGA3 Low

Figure 2. Gene Expression Characterization of ITGA3 in Melanoma Patient Samples: Heat map identifying gene expression shifts from a reference population of key focal adhesion proteins, including ITGA3, in patient samples from the NCI’s TCGA-SKCM (skin cancer melanoma) cohort. 142/420 (33.8%) of melanoma patients sampled had upregulated ITGA3 expression.

Methods

• Identify correlative relationships between FAK knockdown and correlative protein expression through depmap. • Quantify expression of key focal adhesion and identified ITGA3/B1 proteins using western blot. • Treat identified ITGA3 high and low melanoma cell line panel members. • Characterize responsiveness of melanoma cell line panel members to FAK targeting therapeutics via Cell-Titer-Glo (CTG).

Figure 5. ITGA3 High Melanoma Lines Show Significant Sensitivity to FAK FAT domain inhibition, but not FAK kinase inhibition: Table characterizing chosen line response to UA-2012, defactinib, and AdV FRNK. Comparison in ITGA3 high vs. low lines of AdV FRNK viability and UA-2012 compared to defactinib.

Discussion and Conclusions

• ITGA3 expression in melanoma cells lines is predictive of selective sensitivity to FAK FAT inhibitors. • In ITGA3 high cell lines, FAK-FAT mediated survival signaling is more crucial to their survival than FAK kinase activity.

Future Directions

• Establish the predictive efficacy of FAK FAT therapeutics in ITGA3high melanoma cell lines. • Evaluate FAK FAT inhibitor efficacy in advanced ITGA3-high vs. low melanoma models in targeted therapy resistant vs. responsive models. • Define therapeutic synergy between FAK FAT inhibitors and frontline melanoma therapeutics in ITGA3-high melanoma. • Characterize FAK FAT inhibitor-mediated rounding and ECM detachment in ITGA3-high melanoma cells. • Quantify cell rounding and detachment in ITGA3-high melanoma cells following FAK FAT inhibition • Identify delocalization of FAK from ITGA3 and ITGA3 disengagement from local ECM following FAK FAT inhibition. • Define ITGA3-high melanoma cell susceptibility to anoikis following FAK FAT inhibition. • Identify loss of pro-survival, anti-anoikis signaling in ITGA3-high melanoma cells following FAK FAT inhibition.

Acknowledgments

• Broad Institute: Cancer Dependency Map. • NCI grant award to Timothy Marlowe: R37CA065910. • FAKnostics, LLC for providing drug for this study. Figure 4. Melanoma panel of ITGA3 High and ITGA3 Low Cell Lines: Western blot analysis of FA proteins in chosen lines and quantification of ITGA3 and ITGB1 expression in high vs. low lines.

References

1. Saginala K, Barsouk A, Aluru JS, Rawla P, Barsouk A. Epidemiology of Melanoma. Med Sci (Basel). 2021 Oct 20;9(4):63. doi: 10.3390/medsci9040063. PMID: 34698235; PMCID: PMC8544364 2. Hess AR, Postovit LM, Margaryan NV, Seftor EA, Schneider GB, Seftor RE, Nickoloff BJ, Hendrix MJ. Focal adhesion kinase promotes the aggressive melanoma phenotype. Cancer Res. 2005 Nov 1;65(21):9851-60. doi: 10.1158/0008-5472.CAN-05-2172. PMID: 16267008. 3. Takada, Y., Ye, X. & Simon, S. The integrins. Genome Biol 8, 215 (2007). https://doi.org/10.1186/gb-2007-8-5-215

31


#18 Ishika Ishika

Administration of MARY1, a Novel HTR2B Antagonist, Ameliorates Sepsis-Induced Acute Kidney Injury in Mice

32


#19 Nicolle Hipschman

Targeting the FAK-Paxillin Axis as a Treatment Strategy for Hepatic Fibrosis

Targeting the FAK-Paxillin Axis as a Treatment Strategy for Hepatic Fibrosis Nicolle Hipschman, Timothy Marlowe, Michael B. Fallon Department of Internal Medicine, University of Arizona College of Medicine – Phoenix, Phoenix, AZ

Results

Introduction

Proteins Detected Via MS

B

Sirius Red Stain

C

He alt Al hy co p ho C wi He l th Al p C co ho MA l SH

Treatment Group

Methods Experiments with UA-2012

Human Tissue Staining Section FFPE blocks and Perform Sirius red staining or immunohistochemistry

Create 8-10 regions of interest per tissue and analyze using FIJI

Treat LX-2 cells for 24 hr with 10 µM UA-2012 and 2 ng/mL TGFβ

Examine HSC activation via brightfield microscopy

Determine potential targets of UA-2012 via a UA-2012 pulldown-MS

Analyze effect of UA2012 on HSC activation via western blot/RNA sequencing

Analyze disruption of Paxillin/F-actinpaxillin colocalization via IF

0 2. 5 5 10 20 40

-T

G Fβ

Colocalized Intensity Per Cell Rel to -TGFβ

0

[2012] + TGFβ

5 0

0.9311 25 0.1011

[Defactinib] + TGFβ

0.9822

20 15 10 5 0

0 2. 5 5 10 20 40

Colocalized Intensity Per Cell Rel to -TGFβ

15

0.2204 0.9970 0.9998

G Fβ

G Fβ

F-actin Intensity Per Cell Rel to -TGFβ

0 2. 5 5 10 20 40 0.9887

10

[Defactinib] + TGFβ

+TGFβ vs –TGFβ Treatment

2 0

RegEnrich Score

Transcription Factor

RegEnrich Score

2.000 1.928 1.760 1.732 1.709 1.708 1.678 1.657 1.651 1.614

FOXS1 NOTCH3 PKNOX2 TEF HOXC13 ID3 PRDM1 SSBP3 HOXB9 MSX1

2.000 1.789 1.616 1.599 1.569 1.550 1.493 1.462 1.459 1.450

E

μM

5 0

Treatment Group

TGFBI <0.0001 50

Treatment Group

<0.0001

40 30 20 10 0 -TG FB +T GF UA B -20 12

10

10

μM

0.2732

20 15

μM

UA-2012 + TGFβ vs +TGFβ Treatment

Transcription Factor FOXS1 BHLHE40 HIC1 AEBP1 SMAD7 SSBP3 LDB2 SKIL ID3 LEF1

10

μM

0.7384 25

Fold Change Relative to GAPDH

0

MMP7 Fold Change Relative to GAPDH

5

-TG FB +T GF UA B -20 12

0.1305

15 10

μM

+T G vs 2 01

0.4090 20

1 0

Treatment Group

Treatment Group

FOXS1

0

FOXS1

0.0318 0.0437

3 2

10

Treatment Group

ITGA11

ITGA11

4

-TG FB +T GF UA B -20 12

6 4

Fold Change Relative to GAPDH

Fold Change Relative to GAPDH

0.0005 <0.0001

8

-TG FB +T GF UA B -20 12

5 0

10

TGFBI

15 10

μM

2

Groups Compared

33 DEGs

0.0055

Fold Change Relative to GAPDH

MMP7

COL1A2

FN1 <0.0001 20

-TG FB +T GF UA B -20 12

4

Fβ

D

C

6

FN1 COL1A2

Fold Change Relative to GAPDH

Log2Fold Change (Log2FC) Value

Log2FC Values for Genes of Interest

-T G

Treatment Group

<0.0001

5

-T

[Defactinib] + TGFβ

0.4174

0 2. 5 5 10 20 40

0

0.9925 0.9996 20

<0.0001

10

F-actin-Paxillin Colocalization

>0.9999

G Fβ

5

vs

0.0

-T

0 2. 5 5 10 20 40 0.8670

10

Fβ

0.5

Figure 10. Paxillin inhibitor significantly blocks p-FAK, p-Pax, and fibronectin and collagen 1α1 upregulation by TGFβ. HSCs were treated for 24 hr with -TGFβ , +TGFβ , or UA-2012 + TGFβ. A. Western blot panel showing downregulation of p-FAK, p-Paxillin, fibronectin, and collagen 1α1. B. Bar graphs depict the fold change relative to the + TGFβ control +/- SEM (fibronectin n=5, collagen 1α1 n=5, Itgβ1 n=5, , vinculin n=5, p-Pax n=5, paxillin n=5, p-FAK n=5, and FAK n=5).

Figure 5. Diagram of proposed integrin-FAK-paxillin signaling that promotes actin polymerization and HSC-activation. In activated HSCs, focal adhesion proteins are upregulated, i.e. integrin and paxillin. Paxillin can bind to FAK, which allows for greater actin polymerization cell migration during liver fibrosis progression. Signaling downstream by transcription factors mediates genetic changes in the nucleus. If FAK-paxillin are disrupted by UA-2012, actin polymerization and downstream signaling mediating pro-fibrotic genetic changes prevents HSC activation.

0.0421

+T G

10

1.0

-T G Fβ +T G Fβ -2 01 2

-T G Fβ +T G Fβ -2 01 2 U A

Treatment Group

1.5

U A

1 0

μM

2

10

3

0.7995 0.8439 2.0

[2012] + TGFβ

F-actin Intensity F-actin Intensity Per Cell Rel to -TGFβ

He

2,736 DEGs

FAK Fold Change Relative to +TGFβ Control

4

μM

0.0

Fold Change Relative to +TGFβ Control

0.5

10

1.0

0.0319 0.1026

B

0.0

p-FAK

5

0

-T

F-actin

p

rr

0.5

10

10

Treatment Group

1.5

-T G Fβ +T G Fβ -2 01 2

U A

-T G Fβ +T G Fβ -2 01 2

0

U A

1

0.6231

μM

2

1.0

Treatment Group

Treatment Group

Paxillin

0.4049

5

<0.0001 <0.0001 0.0054 0.1074 15

10

-T G Fβ +T G Fβ -2 01 2

0.0

-T G Fβ +T G Fβ -2 01 2

0.5

1.5

U A

1.5 1.0

Fold Change Relative to +TGFβ Control

2.0

Treatment Group

2.0

0.0587

UA-2012 + TGFβ vs +TGFβ Treatment

0.5407 0.9147

μM

2.5

U A

0

Fold Change Relative to +TGFβ Control

10

10

0.0342 0.0192

μM

GAPDH

30 20

p-Paxillin Fold Change Relative to -TGFβ Control

UA-2012

Treatment Group

3

10

ITGβ1 Fibronectin Collagen 1α1

40

0.4685

+TGFβ vs –TGFβ Treatment

Vinculin

ITGβ1

μM

0

-T G Fβ +T G Fβ -2 01 2

2

0.0021

50

U A

6 4

Fold Change Relative to +TGFβ Control

8

p-Paxillin Vinculin

<0.0001

0.0031

μM

10

Fold Change Relative to +TGFβ Control

Paxillin

<0.0001

-T G Fβ +T G Fβ -2 01 2

FAK

+

Collagen 1α1

Fibronectin

U A

Activated Hepatic Stellate Cell

-

+

Fold Change Relative to +TGFβ Control

p-FAK

Quiescent Hepatic Stellate Cell

-

+

μM

UA-2012

-

0.0084

RNA Sequencing Confirms that UA-2012 Inhibits Genes Responsible for HSC Activation

A

10

TGFβ

0.0163 10

Figure 9. UA-2012 disrupts increased FAK-paxillin interaction in activated HSCs. A. Confocal 40X images of Paxillin-(red), F-actin (blue) and DAPI-(white) stained human LX-2 cells (Left) after 24 hours of treatment. B. Bar graphs show paxillin intensity, F-actin intensity, or their co-localized intensity for UA2012 or Defactinib treatment. The values are represented as intensity per cell relative to the -TGFβ treatment +/- SEM (Paxillin Intensity n=5, F-actin Intensity n=5, F-actin-Paxillin Co-localization n=5).

Western Blot Reveals That Paxillin Inhibition Significantly Modulates Inhibits ECM Protein Expression

B

0.9807 0.6551

15

0 2. 5 5 10 20 40

0.1 0.0

Etiology of Liver Fibrosis

0.0051 0.0843 0.3452 0.9975

0.6595

0.1467

G Fβ

0.2

[2012] + TGFβ

0.9998

-T

al

th y

0.0

He

0.9981

He al Al thy co ho C wi He l th Al p C co ho M l AS H

0.1

2 0

F-actin-Paxillin Colocalization

F-actin Intensity

15

Paxillin Intensity

Paxillin Intensity Per Cell Rel to -TGFβ

0.2

>0.9999 0.1687 0.4 0.3

Merged

0.3779

0.9986

Average Percent Area Stained (%)

0.4

4

C

pFAK Y397

0.3

8

-T

5

0

Etiology of Liver Fibrosis

<0.0001

6

G Fβ

Paxillin Intensity Per Cell Rel to -TGFβ

0.4078

10

<0.0001 0.0028 0.0316 10 <0.0001

Fβ

He alt Al hy co ho C wi He l th Al p C co ho MA l SH p

0.0674 15

p

Liver Condition

pFAK Y397

A

B Paxillin Intensity

0.6442

Figure 6. Paxillin and FAK are significantly upregulated in human cirrhotic livers. Representative histological and immunohistochemical (IHC) images (left) and corresponding quantification of (right) of (A,B) Sirius red, (C, D) Paxillin, (E, F) FAK, (G, H) αSMA, and (I, J) pFAK in liver tissue from cirrhotic vs healthy patients, stratified by etiology. Scale bars = 150 µm or 300 µm. Data are shown as mean percent area stained +/- SEM (Healthy n=6, Cirrhotic n=20; Healthy n=6, Alcohol =5, Hepatitis C (Hep C) =5, MASH =5).

Hypothesis: FAK-paxillin inhibitor, UA-2012, disrupts the FAKpaxillin interaction which prevents actin polymerization and cell migration during hepatic stellate cell activation.

10 µM Defactinib +TGFβ

0.9717

Liver Condition

Question: How does our FAK-paxillin inhibitor prevent hepatic stellate cell activation?

10 µM UA2012+TGFβ

<0.0001

He al Al thy co ho C wi He l th Al p C co ho M l AS H

0

+TGFβ

0

Etiology of Liver Fibrosis

Average Percent Area Stained (%)

5

J

-TGFβ

Paxillin

Average Percent Area Stained (%)

A

6 4 2

He

Average Percent Area Stained (%)

0.0106

Figure 8. The paxillin LD2 motif complexes with focal adhesion proteins in HSCs. List of proteins detected via mass spectrometry (MS) in the UA-2012 beads compared to unconjugated beads.

IF Shows That Paxillin Forms Fibers That Co-Localize with F-actin

0.2624

8

αSMA

10

Focal adhesion kinase (FAK) Actin Related Protein 2 (ARP2)

0.1776 10

He

Liver Condition

αSMA

UA-2012 + TGFβ : 10 µM UA-2012 + 2 ng/mL TGFβ

He

C tic

al th y He

Ci rr ho

Average Percent Area Stained (%)

2 0

+TGFβ : 0.1% DMSO + 2 ng/mL TGFβ

Figure 7. Prevention of myofibroblast differentiation by lead peptide. TGFβ induces a myofibroblast-like phenotype. Red arrows denote areas of cell packing. When treated with UA-2012, cells retain the inactivated morphology (UA-2012 + TGFβ).

FAK

4

15

Alpha-parvin

p He 5 0

0.1248

8 6

H ea lth y C irrh ot ic

αSMA

I

-TGFβ : 0.1% DMSO + 4 µM HCL in 1 µg/mL BSA

0.8013

Average Percent Area Stained (%)

UA-2012

Figure 4. The paxillin mimetic is modeled after the LD2 motif of paxillin. It is designed to target binding partners of the paxillin LD2 motif such as the 4helix bundle of FAT-domain of FAK. The peptide is stapled to enhance helicity, permeability, binding, and proteolytic resistance.

10

FAK 0.0012

10

H

G

0.3325 0.0091

20 15

Etiology of Liver Fibrosis

ho tic

FAT Domain

pFAK

(PDB 1OW8)

tic

lth y

0

Ci

α2

α1

Figure 3. Hepatic stellate cells (HSCs) differentiate into myofibroblasts. TGFβ acts on hepatic stellate cells (HSCs) to induce differentiation into myofibroblasts, mediated by FAK and paxillin, which lead to an increase in the production of collagen and fibronectin into the ECM. We have demonstrated that our paxillin-mimetic, UA-2012, designed to inhibit the FAK-paxillin interaction blocks myofibroblast differentiation.

Average Percent Area Stained (%)

5

F

FAK

α4 α3 Native Paxillin LD2 Motif

0.8403

10

ea

Average Percent Area Stained (%)

Paxillin 0.4208

0.0010

H

E

UA-2012 Bound to FAT Domain (PDB IOW8)

Etiology of Liver Fibrosis

Paxillin

15

10

tic

0

20

General transcription factor II-I

0

Liver Condition

UA-2012 Targets FAK-Paxillin Interaction

Integrin-linked protein kinase

10

irr ho

D

C Paxillin

Figure 2. Hepatic stellate cells differentiate into Myofibroblasts by cytokine TGFβ. Chronic liver injury leads to hepatocyte death, which signals to healthy, resident liver cells to release TGFβ. TGFβ is the main activator of hepatic stellate cells that differentiates them into myofibroblasts. Myofibroblasts produce scarring proteins in the liver and lead to loss of liver function. There are no FDA approved treatments for targeting this process.

Talin-1

40 30 20

He alt Al hy co ho wi He l th Al p C co ho MA l SH

10

0.0233 <0.0001

50

-TG FB +T GF UA B -20 12

30 20

H

0.0053

Average Percent Area Stained (%)

<0.0001

lth y

Percent Area of Sirius Red Stain (%)

Sirius Red 50 40

Liver Condition

Figure 1. The progression of hepatic fibrosis from a healthy liver to hepatocellular carcinoma. Liver disease is the tenth leading cause of death in the United States. If hepatic fibrosis is left untreated, it can progress into liver cirrhosis and then hepatocellular carcinoma. This can eventually lead to liver failure, which can lead to death.

Vinculin

0.0273

Sirius Red

MASH

ea

Hep C + Alcohol

Hep C

Alcohol

Healthy

irr ho

A

Pulldown-MS shows that UA-2012 targets Focal Adhesion Proteins & ARP2

Paxillin Inhibitor Prevents Myofibroblast Phenotype

IHC Demonstrates Paxillin & FAK Upregulation & Paxillin Localization to Collagenous, αSMA-Expressing Areas in Human Cirrhotic Livers

U A -2

Hepatic Stellate Cell Activation Leads to Liver Fibrosis

C

Hepatic Fibrosis Progression

Treatment Group

Overlap of Top-Ranked Transcriptional Regulators

FOXS1, ID3, SSBP3

Figure 11. Differential gene expression following TGFβ and UA-2012 treatment. A. Volcano plots comparing +TGFβ vs. –TGFβ (left) and UA-2012 +TGFβ vs. +TGFβ (right). Red and blue indicate significantly up- and downregulated genes, respectively (|FC| ≥ 2, FDR ≤ 0.05). B. Heatmap of genes of interest meeting these criteria. C. qRT-PCR validation of selected genes following –TGFβ, +TGFβ, or 10 µM UA-2012 treatment; expression is shown as 2–ΔΔCT relative to –TGFβ and normalized to GAPDH. D. Top 10 transcription factors associated with gene expression changes for each comparison. E. Euler plot showing unique and overlapping transcription factors between TGFβ and UA-2012 +TGFβ treatments.

Conclusion & Future Directions Conclusions

• Paxillin and FAK are upregulated in human cirrhotic tissues (end stage of liver fibrosis) • Paxillin is localized to collagenous, αSMA-expressing areas in human cirrhotic tissues • UA-2012: • Prevents myofibroblast differentiation upon TGFβ treatment • Significantly reduces p-FAK, p-Pax, and extracellular matrix proteins: fibronectin and collagen 1α1 • Significantly blocked FN1, COL1A2, ITGA11, and TGFBI gene expression induced by TGFβ

Future Directions

• Overexpress paxillin LD2 mutant and FAT mutant and to determine whether it is inhibition of the paxillin LD2 motif or FAT domain that regulates HSC activation • Test disruption of ECM production (mRNA & protein), paxillin fiber formation, and actin polymerization • Evaluating CCl4 mouse model for pFAK, FAK, pPaxillin, Paxillin, and αSMA expression upon UA-2012 treatment • siRNA screen to determine transcription factors that are modulated by UA-2012 to control gene expression of pro-fibrotic genes

Acknowledgements We would like to thank FAKnostics, LLC for making the paxillin mimetic, UA-2012. RNA sequencing was performed by Novogene. We would like to acknowledge Dr. Tobias Jakobi for his assistance with the RNA sequencing analysis, as well as Dr. Shirin Doroudgar and her graduate student, Marjan Fakhrizadeh Esfahani, for their assistance with qRT-PCR. This project was funded by the UA College of Medicine Phoenix Internal Medicine Start Up funds, as well as UA-COMP Department of Internal Medicine Catalyst Funds (#TF007), and the NIH (#42DK71379). Images in the introduction and hypothesis sections were created with BioRender.

33


#20 Robert Hafemeyer

An Agile Deep Learning Virtual Screening Pipeline for Identification of High-Affinity Ligands of Collagen Mutants

Title

Accelerating Lead Discovery for Collagen Disorders An Agile Deep Learning Virtual Screening Pipeline for Identification of High-Affinity Ligands of Collagen Mutants

Robert Hafemeyer*1, Daniel Gonzalez2, Ranel Maqdisi1 & Yuval Mazor1.

Author(s)

1. School of Molecular Sciences, Arizona State University, Tempe, Arizona 2. Department of Computer Science, California Polytechnic State University, San Luis Obispo, California

Background

Hypothesis

● While previous research demonstrated the role of collagen misfolding and alleviation of pathophysiological markers by chemical chaperones, high-affinity small-molecule collagen mutant ligands have not been investigated.

Structure Initialization

● High-affinity ligands stabilize mutant collagen.

Initialize Structures

Methodology

Triple helices initialized as homotrimers with Boltz-2 (n=13)

● Collagen is a structural triple helix conserved across all known animal species.

Filter by Criteria Must form a triple helix (n=9)

● Glycine and Proline are essential for the dihedral angles of the triple helix. ● Collagen disorders comprise diverse genetic disorders affecting collagen. ● Collagen disorders lack specific treatmentsTypeto date. Type I II

Type III

Virtual Screening

Chemical Chaperones vs. High Affinity Ligands

Wild Type vs. Mutant

● Deep learning, through ADMET-AI,

● Traditional docking was performed

was leveraged to filter leads by

to validate virtual screening and

bioavailability, toxicity, and

prepare docked ligand-collagen

drug-likeness

complexes for molecular dynamics.

Future Directions

Acknowledgements

● Longer Sequences (3 x 25 residues)

Abraham, MJ, et al., (2015). GROMACS, SoftwareX.

● More Glycine, Arginine, and Proline Substitutions (5,2,1 → 10,10,10)

Darvell, B. W. (2018). More polymers. In Materials Science for Dentistry (pp. 699-718). Elsevier.

● Physics Application in Boltz-2 Screening with Expanded Lead Library and Composite Scoring

Eberhardt, J., et al.. (2021). AutoDock Vina 1.2.0. Journal of Chemical Information and Modeling.

(4k → 100k) ● Expand AutoDock Screening with GPU (10 → 10k) ● Expand ADMET-AI Screening (43 → 300) ● Improve Pharmacophore through Glide for Refined Leads (30 Diverse Leads) ● GROMACS increase boundary to 2nm (3 → 10 Leads)

● RMSD was significantly higher (p<0.05) in the presence of leads C1 and C3, as well as 29mM PBA, when compared to mutant. ● RMSF was observed to be significantly less (p<0.05) in mutant when compared to WT. This loss was restored in the presence of lead C1 and 29mM PBA, a chemical chaperone.

34

● GROMACS Steered MD (Young’s Modulus, Binding Affinities) ● Atomistic to Microscale: Finite Element Simulations of Chaperone-doped Collagen Matrices ● Circular Dichroism Biophysical Validation ● Enzyme and Integrin Affinities for Mutated and Chaperoned Helices ● Divalent Cation Binding Affinities ● in Vitro Use Case Validation

Flynn, J. M., et. al, (2020). Lovell and Winter’s pediatric orthopaedics (8th ed.). Wolters Kluwer. Gazzotti, S., et. al, (2024). Imaging in osteogenesis imperfecta: Where we are and where we are going. European journal of medical genetics, 68, 104926. Jennewein, D. M., et. al, (2023). The Sol Supercomputer at Arizona State University. Practice and Experience in Advanced Research Computing (pp. 296-301). Association for Computing Machinery, Inc. Passaro S., et. al, (2025). Boltz-2 bioRxiv. Shabani, M., et. al, (2023). Vascular aneurysms in Ehlers-Danlos syndrome subtypes: A systematic review. Clinical genetics, 103(3), 261–267. Sobey G. (2014). Ehlers-Danlos syndrome - a commonly misunderstood group of conditions. Clinical medicine, 14(4), 432–436. Swanson, K., et al. (2023). ADMET-AI bioRxiv.


#21 Jacob Kozora

Design and evaluation of PSMA targeted PIM kinase PROTACs for prostate cancer therapy

Design and evaluation of PSMA targeted PIM kinase PROTACs for prostate cancer therapy Jacob S Kozora1, Ajit Thomas2, Barbara Slusher2, Mudasir Bhat3, Noel A Warfel3, Abhijit A Date1 Click to edit Master title style

1. Department of Pharmacology and Toxicology, R. K. Coit College of Pharmacy, University of Arizona, Tucson, AZ, United States 2. Department of Johns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD, USA. 3. Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC, United States

PSMA Binding

Abstract

Targeted protein degradation of PIM kinases, a family of serine/threonine kinases implicated in prostate cancer (PCa) progression, has been shown to be a more efficacious PCa therapy than classical small molecule inhibition (SMI). PIM PROTACs, "PIMTACs," address a critical limitation of PIM SMIs: PIM protein levels are depleted instead of stabilized, thereby eliminating kinaseindependent, pro-survival functions.

•

The first-generation PIMTAC has anticipated liabilities, including suboptimal pharmacokinetic properties and limited tumor selectivity. To overcome these potential issues, we aim to develop next-generation PIMTACs with enhanced tumor selectivity and controlled activation.

•

Prostate-Specific Membrane Antigen (PSMA) is a clinically validated target for selective PCa therapy.

•

We hypothesized that rationally designed PIMTAC-PSMA conjugates will improve tumor targeting and efficacy while minimizing off-target toxicities.

•

Clinically Validated PSMA-Targeting Drugs O

O O

N

O

O

N

177Lu

N O

N H

H N

N

H N

H N

O

O

O

Pluvicto

O

H N

OH

O OH

O

O

18F

N

H N

OH

H N

O

- PSMA-targeting radioligand therapeutic agent

O

HO HO

O

O

H N O

N

OH

O

O

N

N

O

O H N

N O

N H

N O

HN

O

H N HO

O

H N

H2N HO

O

O

H N

IC50 = 2.0 ± 0.05nM

O

OH

75

O

50

0

-10

-8

-6

-4

N

N

-2

Log (M)

Figure 2: PSMA enzymatic inhibition testing for PSMA-PIMTAC conjugates against 2-PMPA shows potent inhibition (IC50 ≤ 10 nM).

OH

N

O H N

N O

N H

N

H N O

N O

HN

O

H N HO

O

O

H N

OH

O O

OH

EUK-PIMTAC-3 (Carbamate Linker)

S N

Figure 4: New linker designs for PSMA-PIMTACs to enhance plasma stability.

Future Directions

OH

• Western blot studies in both PSMA+ and PSMA- cell lines to determine degradation efficiency and kinetics. • Plasma stability and PK/PD characterization for new carbonate and carbamate linker designs. • Evaluate mechanisms of cellular uptake – passive diffusion vs PSMA endocytosis.

OH

S

OH

OH

EUK-PIMTAC-2 (Carbonate Linker)

N H

O

F F F

25

-25

O

H N O O

O

100

O

N

HN

N

125

OH

O

O

O

O

O

O

S

EUK-PIMTAC-1

OH

H N

O

HO

N

N H

N

- PSMA-targeting PET diagnostic agent

H N

O

F F F

N

EUK

PSMA-PIMTACs Design and Theory O

N

H N

O

O H N

H N

O

O

F F F

O

OH

O OH O

Pylarify

H N

O

PIM Degradation

O

H N

New Linker Designs

DUPA O

% Inhibition

•

Figure 3: PSMA+ cells (LNCaP) treated with PSMA-PIMTAC conjugate (1µM) shows rapid uptake and intracellular PIM degradation compared to parental PIMTAC (1µM)

Plasma Stability Studies

• MD simulations and in silico analyses to investigate PSMA-PIMTAC chameleonicity and membrane permeability • In vivo xenograft mice models with PSMA+ and PSMA- tumors

References (1) J. Med. Chem. (2025) 68 (10): 10139–10155.

Acknowledgements

Figure 1: Schematic representation of the PSMA–PIMTAC strategy. (1)

Table 1: Stability of control and test compounds in mouse and human plasma. PSMA-PIMTAC conjugate half lives and metabolites indicate that the ester linker is a major liability that needs to be optimized.

This work was supported by DoW Grant #HT942524PCRPIDA with Noel Warfel and the COIT Foundation.

35


#22 Ryan Woltz

Utilizing Molecular Dynamics (MD) to Investigate and Enhance Designed Binder Proteins’ Affinity and Specificity to SK Channels

36


#23 Ting-Yun Wang

YAP-Targeted Biomimetic Nanotherapy Suppresses Vascular Inflammation and Stabilizes Atherosclerotic Plaques

37


#24 Rithika Parthasarathy

Targeting Mitochondrial Dysfunction in Parkinson’s Disease Through Modulation of the α-Synuclein–TOM20 Interaction

38


#25 Catherine Vasquez

Small Molecule Z06 Targets Tropomyosin Overlap Flexibility and Improves Systolic Function in a Dilated Cardiomyopathy Mouse Model

39


#26 Phyo Han, Thwin

Targeting Translational Control of the Nrf2 Antioxidant Network to Modulate Ferroptotic Susceptibility in Cellular Disease Models

Targeting Translational Control of the Nrf2 Antioxidant Network to Modulate Ferroptotic Susceptibility in Cellular Disease Models Phyo Han Thwin¹, Nan Jia¹, Zackery Yahiku³, Matthew Boylan²,⁴, Megan Carver¹, Lei Wang¹, Haining Zhu¹,²,⁵

¹Department of Pharmacology and Toxicology, University of Arizona, Tucson, AZ, USA; ²Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ, USA; ³Department of Neuroscience, University of Arizona, Tucson, AZ, USA; ⁴Department of Molecular & Cellular Biology, College of Science, University of Arizona, Tucson, AZ, USA; ⁵Research Service, Department of Veterans Affairs Southern Arizona Health Care System, Tucson, AZ 85713, USA

40

B

0.004

Relative mRNA level

ALS

iMN D35

0

3

6

9

12 15 Hours

18

21

iBEAS-2B-R521G

0.5

0

15 30 min min

1 h

2 h

F

1.5

Nrf2 Translation

GAPDH Translation

✱

ns

2.0

ns

1.5 Fold of iBEAS-2B-WT

0.0

D

F

1.0

0.5

SW T R4 95 X R5 21 G

FU

S-

S-

FU

FU

49 5X

52 1G

S-W T

S-R

0.0

Fold of iBEAS-2B-WT

52 1G

52 1G

FU

iBEAS-2B

ALS

GPX4 / β-actin

xCT / β-actin 1.5

1.5 ✱✱✱

1.0

0.5

0.0

HC

ALS

D35 iPSC-MNs

Fold of HealthControl iPSC-MNs

Fold of iBEAS-2B-WT

β-actin HC

S-W FU S-R T 49 FU 5 S-R X

49 5X

S-W T FU

S-R

S-R

FU

FU

FU

FU

LDH Assay

GPX4

I Fold of HealthControl iPSC-MNs

FU S-W S-R T 49 5 S-R X 52 1G

FU S-W S-R T 49 5 S-R X 52 1G FU

FU

•

0.0

S-R

ALS

H HC ALS

✱✱

1.0

0.5

0.0

HC

ALS

D35 iPSC-MNs

iMN D35

Conclusions

0.0

iBEAS-2B

Fig. 3. SUnSET puromycin labeling shows reduced global and Nrf2specific synthesis (A, B). Polysome profiling (C) shifts Nrf2 mRNA out of polysomes, while β-actin is unaffected (D); eIF4E RNA-IP shows reduced eIF4E–Nrf2 mRNA binding (E, F). iBEAS-2B

HC

0.0

0.3 0.2

0.5

iBEAS-2B

SLC7A11 - xCT

0.1

iMN D35

0.5

iBEAS-2B

C

B

0.5

0.1

G

1.0

MG132 Inhibitor Treatment

1.0

3. Nrf2 mRNA translation initiation is blocked

✱✱

0.2

iBEAS-2B

✱

2.0 1.5

24

FU S-W S-R T 49 5X S-R 52 1G

iBEAS-2B-R495X

FU

Nrf2/β-actin

1.0

Time

1.0

✱✱✱

0.5 0.4

0.3

0.0

F

RSL3 5 μM

0.5 0.0

β-actin

iBEAS 2B

✱

2.5

1.5 1.0

R495X

Fig. 2. Nrf2 transcript abundance (A) and actinomycin D decay kinetics (B) are unchanged. Nrf2 ubiquitination (C), Cycloheximide chase (D, E), and MG132 rescue (F) show no change in turnover.

1.5

0.0

NCOA4 / β-actin

✱ ✱✱

2.0

1.5

0.0

E

ACSL4

0.2

ACSL4 / β-actin 2.5

R521G

iBEAS-2B-WT

A

✱

0.4

D

NCOA4

0.4

0.001 0.000

E

RSL3 5 μM

C

✱✱ ✱✱

0.6

FUS-WT

0.002

FU

D

0.5

RSL3 5μM

0.8

Fig. 4. ARE-driven luciferase output drops (A); iBEAS-2B cells (B) and ALS patient iPSC motor neurons (E-I) become more sensitive to the GPX4 inhibitor RSL3. Anti-ferroptotic effectors SLC7A11/xCT and GPX4 fall (C), while pro-ferroptotic NCOA4 and ACSL4 rise (D).

C

mRNA Decay

0.003

Fold of iBEAS-2B-WT

HC

B Cell Viability (fold Control)

Firefly/Renilla

52 1G

S-R FU

r Em

49 5X

S-W T

Vec to

FU

pty

S-R

49 5X

52 1G

S-W T FU

S-R

S-R

ALS

iMN D35

ns

0.5

FU

• Readouts: SUnSET puromycin labeling, polysome profiling, eIF4E RNA-IP, actinomycin D decay and cycloheximide chase.

HC

Nrf2 mRNA Level

1.0

FU

• Models: human iBEAS-2B, murine N2A-FUS-KO, and ALS patient-derived iPSC motor neurons (iMN D35), using the ALS-linked FUS variants R495X and R521G as the RBP perturbation.

0.5

2. The loss is post-transcriptional, not degradative 1.5

✱✱✱

1.0

iBEAS-2B

E

✱✱✱✱

1.0

0.0

0.0

FU

A

Fold of iBEAS-2B-WT

• We asked whether such variants lower Nrf2 protein by blocking translation initiation, and whether that shifts the ferroptotic threshold.

0.5

Fig. 1. ALS-linked FUS variants R495X and R521G reduce Nrf2 protein in human iBEAS-2B cells (A, B), murine N2A-FUS-KO cells (C, D) and ALS patient-derived iPSC motor neurons (E, F). β-actin is unchanged.

FU

• Cellular stress and disease-associated RNA-binding protein (RBP) variants reshape mRNA-specific translation.

1.0

Cell Viability (fold of Control)

0.0

✱

1.5

Fold of HealthControl iPSC-MNs

0.5

Nrf2 / β-actin

F

✱✱

ns 1.5

Fold of N2A-FUS-KO

✱✱

1.0

• Nrf2 output is set by protein abundance, which depends on transcription, mRNA stability, translation and proteasomal turnover. • Keap1-directed degradation is heavily mined by drug discovery; translational control of Nrf2 is not.

D

✱✱✱✱

1.5

✱✱

1.5

0.0

N2A-FUS-KO

FU

Fold of iBEAS-2B-WT

2.0

ARE-Plenti Luciferase Assay

iMN D35

N2A-FUS-KO

B

A

ALS

β-actin

β-actin

iBEAS-2B

HC

4. Nrf2 loss rewires the ferroptosis axis and lowers the death threshold

Nrf2

Nrf2

0.0

Background

E

C

A

FU

Modulating cellular redox homeostasis and ferroptosis, an iron-dependent, lipid-peroxidation-driven cell death pathway, has emerged as a compelling strategy in drug discovery for both oncology and degenerative disorders. Nuclear factor erythroid 2-related factor 2 (Nrf2) serves as the master transcriptional activator of the endogenous antioxidant and anti-ferroptotic defense network, regulating key effectors including SLC7A11 (xCT) and glutathione peroxidase 4 (GPX4). While traditional drug discovery has focused heavily on Keap1-dependent proteasomal degradation, the upstream mechanisms governing Nrf2 translation remain critical yet underexplored therapeutic targets. Here we identify a selective translational regulatory mechanism that governs Nrf2 protein synthesis and sets ferroptotic sensitivity in human and murine cellular models.

Results

Results

1. Nrf2 protein is reduced across human and murine models

Relative Nrf2 expression

Introduction

• • •

Nrf2 protein is lost through a transcript-selective block at translation initiation, not at the transcript level, mRNA stability, or proteasomal turnover. The block spares housekeeping mRNAs (β-actin, GAPDH), marking it as an mRNA-specific, druggable control point. Nrf2 loss collapses the SLC7A11/GPX4 axis and raises NCOA4 and ACSL4, lowering the lipid-peroxidation threshold. Unlocking Nrf2 synthesis is a tractable, high-value strategy for small-molecule development.

Future Directions

Small-molecule and oligonucleotide screens to de-repress Nrf2 mRNA translation initiation; mapping the 5′ UTR elements and eIF4E-associated factors behind transcript selectivity; and testing whether restored Nrf2 synthesis rescues ferroptotic vulnerability in patient neurons and tumor models.

Acknowledgements

I thank Dr. Haining Zhu and Dr. Lei Wang for their guidance, and the entire Zhu laboratory for their help. This work was funded in part by NIH grants R01NS115507 and R21NS122169, and Department of Veterans Affairs awards I01BX002149 and IK6BX006316-01 to H.Z. Contact: phyohanthwin@arizona.edu


#27 Jeanelle Castro

G3BP1 Ligands Modulate Stress Granules and Suppress Triple Negative Breast Cancer Proliferation

Suppression of Triple Negative Breast Cancer Proliferation Via Stress Granule Modulation

Suppression of Triple Negative Breast Cancer Proliferation Via Stress Granule Modulation Click to edit Master title style Jeanelle Castro, Rukayat Aromokeye, Lei Wang, Savio Cardoza, Gregory Thatcher*, Haining Zhu* Department of Pharmacology & Toxicology, Skaggs Pharmaceutical Center, College of Pharmacy, The University of Arizona, Tucson

Abstract

Cellular Validation A.

DMSO

SC1-121

SC1-126

SC3-182

SC4-002

Long-Term Cell Survivability

USP10P

IgG

A.

DMSO

B.

Cisplatin

USP10 DMSO G3BP1

Caprin1

SC1-121

B.

Eif3η

Endo-G3BP1

Merged

C.

DMSO

C.

SC1-126

DMSO

SC1-121

High Throughput Screening

SC1-126

A.

+0.5 mM Cisplatin

• Stress Granules (SGs) are ribonucleoprotein condensates, regulated by nucleator G3BP1 (Ras GTPase-activating protein-binding protein 1). • Triple negative breast cancer (TNBC) cells manipulate SGs and overexpress G3BP1 to evade apoptosis and regulate translational reprogramming. • Time-resolved fluorescence resonance energy transfer (TR-FRET) screening identified small-molecule ligands that disrupt G3BP1 NTF2L domain interactions and suppress SG formation. • Hit compounds were characterized in-vitro to reduce SG formation and sensitize TNBC cells to cisplatin (CDDP) treatment. • Combinatory treatment increased DNA damage signaling and apoptosis, as well as decreased the clonogenic survivability rate.

SC3-182

D.

SC3-182 USP10-PEP

USP10-PEP G3BP1 in complex with Caprin1

G3BP1 in complex with USP10

G3BP1 in complex with USP10 and caprin1

B.

C.

Figure 2: MDA-MB-231 cells treated overnight with DMSO or G3BP1 ligands (A) USP10 and Caprin-1 Co-IP with G3BP1 (B) SG Formation (C) Cell Viability (D) MDA-MB231 G3BP1 KO Cell Viability.

Target Engagement B.

ns

SC3-182

SC1-121

CDDP

0.0

+ 40 M Cisplatin

Figure 1: (A) Crystal Structure of G3BP1 (B) TR-FRET assay principle (C) lead compound optimization.

✱✱✱

✱

10

Future Directions • Studies using MDA-MB-231-G3BP1-KO tumors and a syngeneic model of 4T1 cells in BALB/c mice. • G3BP1-mediated SGs across TNBC subtypes, like MDAMB-157 or BT549. • Synergism with doxorubicin, Taxol (paclitaxel), or PARP inhibitors. • Flow cytometry single-cell FACS (fluorescent activated cell sorting) for apoptotic signaling pathway activation.

Acknowledgements

5 0 SC3-182

0.5

✱

15

CDDP

✱

20

SC1-121

ns

1.0

ns

✱✱

DMSO

✱

✱

Relative PARP1 Levels (Normalized to Alpha-Tubilin)

1.5

DMSO

Relative BCL-XL Levels (Normalized to Alpha-Tubilin)

A.

Figure 4: (A) Representative clonogenic growth of MDA-MB-231 cells (B) Quantification of G3BP1 ligands (C) Quantification of G3BP1 ligands with Cisplatin.

+ 40 M Cisplatin

Figure 3: Effects of G3BP1 ligands on apoptotic signaling.

• • • • • •

Dr. Haining Zhu Dr. Lei Wang Dr. Chunlong Ma Dr. Megan Carver Dr. Phyo Han Thwin Dr. Rukayat Aromokeye

• • • • • •

Tahsin (Neel) Reaz Ahmed Chase Kappel Israel Levi Aispuro Wen-Yi Chiu Matthew Boylan Alexis Shwartzberg

Supported by NIH/NINDS R01NS115507 Grant

41


# 28 Sean Ginn

Design, Synthesis, and Evaluation of a DYRK1A Degrading PROTAC Scaffold Using Known Small Molecule Inhibitors

42


#29 Vishal Kaleeswaran

Development of DYR533, a highly selective and orally bioavailable inhibitor of DYRK1A toward the treatment of Alzheimer’s Disease and/or Down Syndrome

Development of DYR533, a highly selective and orally bioavailable inhibitor of DYRK1A toward the treatment of Alzheimer’s Disease and/or Down Syndrome Vishal Kaleeswaran,c Christopher Foley,a Samantha K Bartholomew,b Wendy Winslow,b Ramon Velazquez,b Travis Dunckley,b,d and Christopher Hulme a,c,d a Department of Chemistry & Biochemistry, The University of Arizona, Tucson, AZ 85721 b The Arizona State University-Banner Neurodegenerative Disease Research Center, Tempe, AZ 85287 c R. Ken Coit College of Pharmacy, Medicinal Chemistry, The University of Arizona, Tucson, AZ d Iluminos Therapeutics LLC Corresponding Authors: kvishal@arizona.edu, hulme@arizona.edu

Harmine

KinomescanTM

DYRK1A KD 16 nM (n = 2) DYRK1A IC50 34 nM DYRK1B IC50 29 nM PAMPA 265 nm/s Caco-2 Papp (10-6 cm/s) A→B 5.71, B→A 3.13 P-gp Efflux ratio 0.5 tPSA 54 Å2, cLogP 4 Microsomal Stability MLM CL 89.5 μL/min/mg Kinetic Sol. (pH 7) 0.3 μg/ml Oral Bioavailability (CD-1 mouse) 0% T1/2 6 mins (plasma), 15 mins (brain) S(35)-selectivity (468 kinases) 0.19 @ 10μM

Delay of Tau pathology

Delay of Amyloid plaque formation

•

However, DYR219 has limited solubility, poor metabolic stability, and no oral bioavailability

12.5 mg/kg

O

NH

N N H

Conserved Lysine Pocket

N

An analog of SM07883 (PCT Markush in red) Solvent Exposed Region

Region A Region B Region C

• •

Synthetic Route:

Overexpression of DYRK1A promotes pathological hallmarks of AD due to hyperphosphorylation of tau, presenilin 1, and amyloid β precursor protein

Structure-based approach for a type I inhibitor Harmine and D15 led to hybrid molecule maintaining key interactions with hinge and conserved lysine pocket

*DYR533 is devoid of hERG and GSK-3β activity, with overall excellent kinome selectivity *SM07883 was in Phase 1A clinical trials for Fronto-Temporal Dementia (FTD)

Development Candidate: DYR533 KinomescanTM

Data Package:

Reduction of total systemic TNFα in 3xTg-AD

Dyrk1A KD 1.4 nM, IC50 6 nM Dyrk1B KD 11 nM MDR1/MDCK Moderate Permeability PAMPA 54.8 nm/s (High Permeability) Caco-2 Papp (10-6 cm/s) A→B 11.93, B→A 36.02 RSK4 P-gp efflux ratio 3.02 Microsomal Stability T1/2 (min) MLM 142, HLM > 148.1, RLM 114.4, DLM > 255.6, CLM 62.5 False Hepatocyte Stability T1/2 (min) HLH > 216.8 Positive RLH 79.3 MLH > 216.8 DLH > 216.8 CLH 157.5 DYRK1A Plasma Protein Binding 80.99 – 91.21% (5 species) tPSA 78.81 Å2, cLogP 3.06, pKA 2.6 & 6.25 Kinetic Sol. (pH 7) 79.88 g/ml, log D 2.49 S(35)-selectivity(468) 0.028 @ 1  M Oral Bioavailability (CD-1 Mouse) 100% Follow-up KDs: Dyrk1a 1.4 nM Dyrk1b 11 nM T1/2 4.18 h, CL 6.92 ml/min/kg, Vdss 10.7 L/kg Dyrk2 35 nM Clk1 13 nM Clk2 59 nM Clk3 530 nM B/P ratio 0.302 Clk4 26 nM RSK4 >10  M Oral Bioavailability (Rat) 81%, T1/2 1.57 h, CL 38 ml/min/kg, Vdss 4 L/kg Degradation of DYRK1A B/P ratio 0.47 Micronucleus Genotox: Clean TD Cyp Inhibition: Clean Eurofins Safety Pharmacology (87): Selective P450 Inhib. (IC50) 1A2 15.1 µM, 2C9 37.1 µM, 2C19 >50 µM, 2D6 >50 µM, 3A4 >50 µM. hERG IC50 14.85 µM.

Quantifying NFT formation through AT8 staining (did not reach statistical significance) 2-month Treatment (Mice 10 months old)

3xTg-AD Vehicle

3xTg-AD mice displayed a delay in tau and amyloid pathology when treated with DYR219

N

N

12.5 mg/kg

•

Competitive Landscape

D15

Hinge Binding Region

Proof of Concept: DYR219 Data Package:

Design Approach

Biological Rationale

Background By 2050, Alzheimer’s Disease (AD) is projected to affect 106 million people worldwide. Currently, there are no effective therapies to ameliorate the pathological progression and the associated cognitive deficits in AD. Therefore, targeting AD pathology via a single pathway is likely impossible, and a successful therapeutic strategy may require pleiotropic interventions. Dual specificity tyrosine phosphorylation regulated kinase-1A (DYRK1A) is an emerging target for the treatment of neurodegenerative diseases, as it has functional activity on multiple pathways implicated in AD and neuronal function. Through selective inhibition of DYRK1A, it may be possible to reduce both amyloid precursor protein (APP) dysregulation and tau hyperphosphorylation. The hyperphosphorylation of the microtubule-stabilizing protein tau contributes to tau dysfunction and aggregation into neurofibrillary tangles (NFTs), which strongly correlates with the severity of dementia in AD. The DYRK1A gene is also located within the Down Syndrome (DS) critical region on chromosome 21, and its overexpression is a significant contributor to the underlying neurodevelopmental and AD-like pathology associated with DS.

3xTg-AD DYR533 2.5mg/kg

Reduction of AD-like pathology in Ts65Dn

Modest reduction of Aβ40 and Aβ42 in 3xTg-AD

Reduction of phosphorylated Tau at disease-relevant epitopes in 3xTg-AD

3xTg-AD DYR533 1.0mg/kg

3xTg-AD DYR533 5.0mg/kg

Conclusions and Future Directions

References

• A ten-year effort has led to the discovery of DYR533: a highly selective, orally bioavailable, brain-penetrant, well-tolerated small molecule inhibitor of DYRK1A which upon dosing in the 3xTgAD model elicits reductions in phospho-tau in a dose dependent fashion. • DYR533 shows dose-dependent reduction of AD-like pathology in the Ts65Dn model of Down Syndrome. • DYR533 also rescues degeneration and behavioral deficits of in vivo drosophila models of AD and DS. (Zhu B. et al, Scientific Reports., 2022) • DYR533 has been manufactured in GMP-grade and is ready for pre-IND toxicology studies in two species.

Wegiel, J.; Gong, C. X.; Hwang, Y. W. The Role of DYRK1A in Neurodegenerative Diseases. FEBS Journal 2011, 278 (2), 236–245. Liu, F.; Liang, Z.; Wegiel, J.; Hwang, Y.; Iqbal, K.; Grundke‐Iqbal, I.; Ramakrishna, N.; Gong, C. Overexpression of Dyrk1A Contributes to Neurofibrillary Degeneration in Down Syndrome. The FASEB Journal 2008, 22 (9), 3224–3233. Velazquez, R., Meechoovet, B., Ow, A., Foley, C., Shaw, A., Smith, B., Oddo, S., Hulme, C., Dunckley, T. Chronic Dyrk1 Inhibition Delays the Onset of AD-Like Pathology in 3xTg-AD Mice. Mol. Neurobiol., 2019, 56, 8364-8375. Melchior, B.; Mittapalli, G. K.; Lai, C.; Duong-Polk, K.; Stewart, J.; Güner, B.; Hofilena, B.; Tjitro, A.; Anderson, S. D.; Herman, D. S.; Dellamary, L.; Swearingen, C. J.; Sunil, K. C.; Yazici, Y. Tau Pathology Reduction with SM07883, a Novel, Potent, and Selective Oral DYRK1A Inhibitor: A Potential Therapeutic for Alzheimer’s Disease. Aging Cell 2019, 18 (5), 1–14. Smith, B.; Medda, F.; Gokhale, V.; Dunckley, T.; Hulme, C. Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimers? ACS Chemical Neuroscience 2012, 3 (11), 857–872. Hulme, C.; Foley, C. Small Molecule Inhibitors of DYRK/CLK and Uses Thereof. 20200039989, 2020. Bartholomew, S. K., Turk, J., Winslow, W., Foley, C., Shaw, A., Rokey, S., ... & Velazquez, R. Dyrk1a inhibition with the novel compound DYR533: a cross-disease therapeutic strategy targeting amyloidosis, tau pathogenesis, and neuroinflammation. bioRxiv 2026

• DYR533 shows a dose-dependent reduction of hyperphosphorylated tau epitopes relevant to disease progression. • DYR533 also reduces AD-like pathology in Ts65Dn model of Down syndrome. • DYR533 induces the degradation of DYRK1A by inhibiting tyrosine autophosphorylation • Successful completion of GMP-grade manufacturing of DYR533 (1.5 kg).

Acknowledgements Alzheimer's Drug Discovery Foundation GN (2013749) NIA (1R01NS109422-01A1) BIO5 ‘Accelerate for Success Pilot Grant’ Award Tech Launch Arizona ‘Asset Development Award’ ADDF-Harrington Discovery Scholar Program ASU Edson Seed Grant to TD Disclosure: CH and TD are co-founders of Iluminos Therapeutics LLC who have licensed DYR533 for further development

43


#30 Leonardo V. C. Correa

Targeting Gilteritinib-Resistant Acute Myeloid Leukemia: Discovery of Novel Small-Molecule Therapeutics

44


#31 Alexis Schwartzberg

Modulating Nonsense-Mediated mRNA Decay to Restore Tumor Suppressor Expression in Cancer

45


#32 Juhaer Anjum

Exploring the biphenyl sulfone structural motif for non-lipogenic ABCA1 induction

46


#33 Garrett Hauck

Small Molecule Compound that Restores Cardiac Thin Filament Calcium Exchange Alters Myocellular Function in a Murine Model of Hypertrophic Cardiomyopathy

Small Molecule Modulation of Thin Filament Calcium Exchange: Effects on Structure and Function Garrett T. Hauck1, Romi L. Castillo2, Rhyaan Mohran2, Jil C. Tardiff1,2

1Department of Cellular & Molecular Medicine, University of Arizona, Tucson, AZ, USA, 2Department of Biomedical Engineering, University of Arizona, Tucson, AZ, USA

Thin Filament Structure

Introduction

Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy and has been definitively linked to mutations in genes encoding the protein components of the cardiac sarcomere, including the cardiac thin filament (CTF). Our lab and others have shown that the structural alterations of distinct regions of the CTF translates to robust functional changes, specifically with regard to the N-terminus of cardiac troponin I (cTnI) and the dissociation of calcium from cardiac troponin C (cTnC)1. Additionally, we have shown that HCM-associated CTF mutations can perturb calcium dissociation2, and hypothesize that accelerations in calcium dissociation kinetics can trigger downstream activation of pathological signaling. Specifically, we have noted that mice expressing the R92W point mutation in cardiac troponin T (cTnT-R92W) have elevated Ca/Calmodulin-dependent kinase II (CaMKII) activity3, and cTnT-R92W CTFs have accelerated calcium dissociation kinetics2. Thus, we hypothesize that a small molecule which decelerates calcium dissociation can (1) ameliorate deficits in CTF function due to point mutations and (2) abolish the potential trigger for CaMKII activation and prevent deleterious signaling in the cardiomyocyte.

To investigate the effects of P2O22 on thin filament structure, we performed Time Resolved-Fluorescence Resonance Energy Transfer (FRET) experiments focusing in on the N-terminal tail of cTnI, as we know structural changes in this region correlate strongly to changes in Ca2+ dissociation rate1. cTnC was labeled with the donor probe IAEDANS at residue Cys84, and cTnI was labeled with the acceptor probe DABMI at residue Ala28Cys. Measurements were taken with and without Ca2+, and P2O22 treatment was 30µM.

Figure 4. (Top Left) Molecular schematic of relevant structures for FRET experiments. Colored beads correlate to the labels in the cartoon below. (Bottom Left) Cartoon model of relevant structures for FRET experiments. (Top Middle) Distance and (Bottom Middle) Distribution of distances between FRET probes. (Top Right) Representative gaussian plots based on measured distances and distributions.

Figure 1: (Left) Calcium exchange events with cTnC. (Right) Atomistic model4 of a single cTn core atop a CTF with F-actin in gray, tropomyosin in green/orange, cTnC in brown, cTnI in magenta, and cTnT in cyan. The red arrow indicates the bead representing the R92W mutation in cTnT.

Structure/Function-Based High-Throughput Screen To identify compounds that bind to the CTF and induce structural changes that are likely to affect calcium exchange, we used a highthroughput time-resolved fluorescence (TR-F) screen with the probe IANBD conjugated to cTnI-A28C (provisional patent no. 63/644,761 to RC and JCT) followed by a secondary screen using stopped-flow calcium dissociation kinetics with IAANS conjugated cTnC-T53C. Primary Screen Secondary Screen

Myocellular Mechanics To investigate the effects of P2O22 on cellular function, we isolated ventricular myocytes from 2-month-old cTnT-R92W mice and their Nontransgenic (NT) littermates and recorded sarcomere length (SL) measurements and calcium transients using FURA-2 AM. Cells were treated with 5 µM P2O22 and paced at 2 Hz.

Figure 2. (Left) Results of the primary screen. (Middle) Results of the secondary screen, with the compound of interest, P2O22, boxed. (Top Right) Effects of 30µM P2O22 on calcium dissociation in wild type CTFs. (Top Left) Representative traces for the bar plots above.

Binding Validation and In Vitro Function

We aimed to apply P2O22 to the cTnT-R92W mutation as it is known to have accelerated Ca2+ dissociation kinetics2. We measured the effects of P2O22 on Ca2+ dissociation from cTnT-R92W CTFs and additionally used isothermal titration calorimetry to directly validate that P2O22 binds to both wild-type and cTnT-R92W CTFs and isolated troponin complexes.

Troponin Complex

Thin Filament

Figure 4. (Top and Bottom Left to Middle-Right) Representative traces and parameters for SL transients. (Bottom Right) Baseline Ca2+ levels measured by FURA-2 AM. n=19-33 cells per mouse; N=5-6 mice per group. **p<0.01, ****p<0.0001 vs. NT + DMSO, ####p<0.0001 vs. R92W + DMSO

Future Directions

Conclusions • Structure/function relationships in the CTF can be harnessed to develop a high-throughput screening pipeline • Structure/function-based high-throughput screen identified small molecule compounds that modulate CTF calcium dissociation - P2O22 significantly decelerates calcium dissociation rate and binds to CTFs with nanomolar affinity • P2O22 significantly reduced the distances between the N-lobe of cTnC and the N-terminal tail of cTnI while increasing order • P2O22 alters cellular contractility, reducing the duration of length transients • P2O22 beneficially reduces baseline calcium levels

1. Titration curve to ID dose that corrects cTnT-R92W Ca2+ dissociation rate without overshooting a) Cell experiments with this optimized dose 2. Stopped-flow calcium association kinetics with P2O22 3. Evaluate changes in SR load with P2O22 4. Evaluate structural changes with other FRET pairs 5. Evaluate the effects of P2O22 on other CTF mutations with accelerated calcium dissociation kinetics (i.e. cTnT-I79N) 6. Evaluate the effects of other compounds that slow calcium dissociation on cTnT-R92W (i.e. P4I7, P6F15) 7. In vivo treatment of cTnT-R92W mice with P2O22

Acknowledgements Figure 3. (Left) Calcium dissociation kinetics of WT and cTnT-R92W CTFs at baseline and with P2O22 treatments. (Middle-Left) Representative traces for the bar plots to the left. (Middle-Right) Binding enthalpy and binding affinity of P2O22 for WT and cTnT-R92W troponin complexes measured by ITC. (Right) Binding enthalpy and binding affinity of P2O22 for WT and cTnT-R92W CTFs.

Tardiff Laboratory Jil Tardiff MD, PhD Melissa Lynn, PhD Catherine Vasquez Andrew Kim, BS

Rhyaan Mohran Zacariah Murrieta Camila Amezquita Garcia Emma Brown

Funding

NIH F31HL178018 (GTH) NIH T32HL007249 (GTH) NIH R01HL075619 (JCT) NIH R01HL172871 (JCT)

References

1. Castillo et al., in prep. 4. Manning, Williams, 2. Williams et al., PNAS Baldo, Mason, and Hei, 3. Lehman et al., Circ UA Schwartz Lab

47


#34 Yashika Garg

Development and characterization of natamycin nanosuspensions for improved ocular delivery

48


#35 Chase Kappel

Small-Molecule G-Quadruplex Binders Induce Cytostasis and Alter TBK1 Signaling in Ewing Sarcoma

49


#36 Farinaz Soleymani

Discovery of Epoxysuccinates as Potent, Covalent Inhibitors of SARS-CoV-2 Papain-Like Protease (PLpro)

Discovery of Epoxysuccinates as Potent, Covalent Inhibitors of SARS-CoV-2 Papain-Like Protease (PLpro)

Farinaz Soleymani2≠, Ganga Reddy Velma1≠, Zhengnan Shen1, Cameron Holberg1, Jiqiang Fu1, Divakar Indukuri1, Soumya Reddy Musku1, Elizaveta Lazarova6, Steve Slilaty4, Zuomei Li4, Kiira Ratia5, Rui Xiong1, Gregory R J Thatcher1,2* 1Department of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA; 2Department of Chemistry & Biochemistry, Colleges of Science and Medicine, University of Arizona, Tucson, AZ 85721, USA; 3Department of Microbiology, College of Medicine, University of Illinois at Chicago (UIC), Chicago, IL 60612, USA; 4Sunshine Biopharma Inc., 333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, Florida 33301, USA; 5Research Resources Center, University of Illinois at Chicago (UIC), Chicago, IL 60612, USA; 6Department of Immunology, College of Medicine, University of Arizona, Tucson, AZ 85721, USA; 6Department of Cellular and Molecular Biology, Collage of Science, University of Arizona, Tucson, AZ 85721, US

Pro248 Tyr264

Asn267

ZN-5-175 (T1/2= 45.1 min) ZN-5-190 (T1/2= 950.3 min)

50

0

Pro299

XR8-23 (T1/2= 3626 min)

ZN-5-191 (T1/2= 834.7)

0

100

Verapamil W NADPH Verapamil W/O NADPH ZN-5-191 W NADPH (T1/2=18 min) ZN-5-191 W/O NADPH (T1/2=16.8 min)

50

0

100

20

40 Time (min)

60

ZN-5-191 W NADPH (T1/2=12.1 min)

ZN-5-191 W/O NADPH (T1/2=15.5 min)

0

0

Verapamil W NADPH Verapamil W/O NADPH

50

0

20

40

CES-mediated hydrolysis is a plausible metabolic pathway

ID-4-2 IC50 = 0.03 µM % inh.= 44 Log 2-(ΔΔCT)= -0.21

IC50 = 0.046 µM CC50= 7.2 µM % inh.= 70 Log 2-(ΔΔCT)= -0.54

GR-3-148 IC50 = 0.017 µM % inh.= 66 Log 2-(ΔΔCT)= N/A

ZN-5-175 IC50 = 0.004 µM % inh.= 98

ZN-5-121 IC50 = 0.06 µM

Linker discovery led to low nM potency

Modifications on R1, R2,R3 and linker

R1: Strong anti-viral activity & human plasma stability

SUN-048 IC50 = 1.3 µM CC50= 121 µM % inh.= 0 Log 2-(ΔΔCT)= -0.17

FS-1-146

FS-1-112

R2 modification to extend binding/gain potency

linker modification→ → loss of potency

FS-1-91 IC50 = 0.017 µM CC50= 11.5 µM % inh.= 68 Log 2-(ΔΔCT)= -7.26

IC50 = 0.007 µM CC50= 12.4 µM % inh.= 90 Log 2-(ΔΔCT)= N/D

SUN-040 IC50 = 0.022 µM % inh.= 56 Log 2-(ΔΔCT)= -6.27

R3: Gain of metabolic stability/antiviral activity

FS-1-148 IC50 = 0.004 µM CC50= 67 µM % inh.= 99 Log 2-(ΔΔCT)= -7.00

Optimized Lead

GR-3-150 IC50 = 0.021 µM CC50= 50 µM % inh.= 58 Log 2-(ΔΔCT)= -0.11

• Potency evaluated using Z-RLRGG-AMC as fluorogenic substrate to run Fluorescent Intensity assay, and signals were recorded after 6 min pre-incubation time. • Antiviral efficacy measured in a RT-qPCR assay in A549 ACE2/TMPRSS2 infected cells (MOI=0.01), in the presence of 1 µM inhibitor. Nirmatrelvir used as positive control.

Pharmacokinetic Profile of Selected Compounds in Mouse and Hamster

Lung (190)

40000

Plasma (191)

400000

30000

Lung (191)

20000

200000

10000 0

0

50

Dose, mg/kg

100

[ZN1-191] ng/mL

[ZN1-190], ng/mL

50000

Plasma (190)

Reaction Conditions; (I) STEP-1: Ti(OEt)4, THF, 70 °C, overnight. STEP-2: NaBH4, -78 °C, 3 h; (II) Pd(dppf)Cl2, Na2CO3, 1,4-dioxane:H2O (5:1), N2, 100 °C, 6 h (III) XPhos Pd G2, K3PO4, 1,4-dioxane:H2O (5:1),N2, 100 °C, 6 h; (V) 4N HCl in 1,4-dioxane, rt.

0

✓ Three i.v. doses (10, 30 & 100 mg/kg) ✓ 2-day study, No effect on body weight ✓ No behavioral/visual signs of distress

• Lead compounds demonstrated short half-life in mouse and hamster • Metabolite ID studies showed hydrolysis of the hydrazide linker is the major instability source.

• Initial DMPK studies → Informed our strategy • Metabolic stability evaluation → Precise mapping of the metabolic soft spot Future Strategy: Develop co-administration protocols (analogous to Paxlovid). Explore novel delivery methods to shield the inhibitor.

References

Tolerability Assessment 600000

Summary and Future Direction Key Findings and Future Direction

R2: Explore original naphthalene of GRL0617- no improvement

Chemistry

DMPK Studies

60

Time (min)

200

Time (min)

• Target remote BL2 loop/groove • Engage and active site Cys111 by extending through a linker and incorporating an electrophilic warhead.

50

% Remaining

100

Gln269

IC50 = 0.023 µM CC50 >75 µM % inh.= 70 Log 2-(ΔΔCT)= -6.8

Significance: PLpro inhibition is a promising antiviral strategy that blocks viral replication and restores host immune response

PROPANTHELINE

ZN-5-191 Microsmal stability in HLM

ZN-5-191 Microsmal stability- MLM 100

In Vitro Human Plasma Stability Tyr268

R1:

Shallow binding pocket→ → Challenging inhibitor design

Human and Mouse Liver Microsomes

Glu167

Asp164

% Remaining

• The emergence of SARS-CoV-2 in late 2019 caused a global pandemic • The virus uses its spike (S) protein to bind to the ACE2 receptor, enabling entry into host cells. • PLpro, an important SARS-CoV2 protease, plays a dual role — processing viral polyproteins and acting as a deubiquitinase/deISGylase, helping the virus evade host immune responses.

Microsomal Stability

Inhibitor Design and Structure-Activity Relationship From Non-Covalent to Covalent PLpro Inhibitors- A Structure guided design to engage Cys111

% Remaining

Introduction and Background PLpro As a Key Protease in SARS- CoV-2

• Shen, Z., et al., Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity. Journal of Medicinal Chemistry, 2022. 65(4): p. 2940-2955. • Velma, G.R., et al., Non-Covalent Inhibitors of SARS-CoV-2 Papain-Like Protease (PLpro): In Vitro and In Vivo Antiviral Activity. J Med Chem, 2024. 67(16): p. 13681-13702. • Ratia, K., et al., Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme. Proc Natl Acad Sci U S A, 2006. 103(15): p. 5717-22. • Ratia, K., et al., A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A, 2008. 105(42): p. 16119-24. • Rouch, C.C., et al., Synthesis and Structure-Activity Relationship of Covalent Inhibitors of SARS-CoV-2 Papain-Like Protease with Antiviral Potency. Bioorganic & Medicinal Chemistry Letters, 2025. 116: p. 130034. • Sanders, B.C., et al., Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2. Nature Communications, 2023. 14(1): p. 1733. • Tan, B., et al., Structure-Based Design of Covalent SARS-CoV-2 Papain-like Protease Inhibitors. Journal of Medicinal Chemistry, 2024. 67(22): p. 20399-20420.

Acknowledgements Reaction Conditions: (VI) Methyl acrylate, Pd(OAc)2, NaHCO3, DMF, N2, 100 °C; (VII) H2, Pd/C 10%, MeOH, HOAc, rt; (VIII) LiOH.H2O THF:H2O:MeOH, r.t; (IX) TMSCl, MeOH, (CH3)C(OCH3)2, rt; (X) HATU, DMAP, DIPEA, DCM, rt; (XI) N2H4•H2O,EtOH, reflux; (XX) EDCI, HOBt, NEt3, DMF, 0°C to rt; (XXX) HATU, DMAP, DMF, 0 °C to rt

Supported by a sponsored research agreement from Sunshine Biopharma LLC.

Supported in part by NIH R01AI168165 to RX


#37 Darpan Raghav

Cryo-EM guided discovery of substrate entry and exit channel inhibitors in Candida drug resistance protein 1 from Candidozyma auris

51


#38 Ajibola Adelakun

The Interplay of G-Quadruplexes and R-Loops in Ewing Sarcoma Cell Survival

The Interplay of G-quadruplexes and R-loops in Ewing Sarcoma Cell Survival Ajibola D. Adelakun1,2,4, Mozani Zianti1, Chase Kappel3, Valery Thompson1, Haining Zhu3, Jacob C. Schwartz1,4 Click to edit Master title style

1 Department of Pharmacology, University of Arizona College of Medicine, Tucson AZ , 2 Department of Pharmaceutical Sciences, University of Arizona College of Pharmacy, Tucson, AZ,

3 Department of Pharmacology & Toxicology, University of Arizona College of Pharmacy, Tucson, Az, 4 University of Arizona Cancer Center, University of Arizona, Tucson AZ

Introduction and Background Maintaining genomic stability is fundamental for cellular health and disease prevention, particularly in the context of cancer. During transcription and replication, cells encounter various structural challenges within DNA and RNA. Notable among these are G-quadruplexes, fourstranded structures formed by guanine-rich sequences, and R-loops, which are RNA-DNA hybrids. These non-canonical structures pose significant obstacles to replication and transcription, frequently leading to genomic instability by creating conflicts between these vital cellular processes. The resolution of these complex nucleic acid structures is paramount to preserving genomic integrity. To explore the implications of these structures in drug discovery, researchers use Ewing sarcoma cell lines to test how candidate compounds affect tumor cell growth and survival. Drug screening evaluates a compound panel for antiproliferative activity, and promising hits are tested in combination, using a synergistic approach to see if paired agents outperform single drugs at lower doses. Effects are measured through relative cell count, viability assays, and cell cycle analysis by flow cytometry, which detects arrest or sub-G1 death. Together, these experiments can reveal novel therapeutic strategies for Ewing sarcoma and related diseases.

Results Figure 3: Viability test

Figure 4: Dose response: Ewing cells vs Non-Ewing cells

Methods Figure 2: Fluorescence-based Assay - G4-stabilizer screen Compounds were screened using a fluorescence melting assay. At the test temperature, G4DNA unfolds and fluoresces. A compound that stabilizes G4DNA keeps it folded, so the fluorescence stays quenched.

52

Discussion and Conclusion Our research illuminates the complex interactions between Gquadruplexes (G4s), R-loops, and specific helicases in maintaining genomic stability within cancer cells, showing that G-quadruplextargeting compounds inhibit Ewing sarcoma proliferation. We identified four compounds out of 30 that demonstrated significant effects on A673 cells, with enhanced efficacy in cells lacking the EWS::FLI1 fusion protein and found that G4 abundance and transcriptional addiction serve as predictive biomarkers of drug sensitivity. The EWS::FLI1-dependent response suggests a possible avenue for targeted Ewing sarcoma therapy. Further work will define the mechanism behind this selectivity. Our findings emphasize the importance of further investigating the specificity and effectiveness of G4-targeting compounds, laying the groundwork for future research aimed at leveraging these molecular interactions to develop novel therapeutic strategies in cancer and beyond.

Figure 1: Formation and resolution of G4s and R-loops. Mechanism of G4s and R-loop formation. Most R-loops form cotranscriptionally in cis when an mRNA transcribed by RNAPII reinvades and anneals to the template strand. RNAPII pausing at the 5′ end of genes can result in negative supercoiling which favous R-loop formation. The non-template, singlestranded component of R-loops can further fold into G-quadruplex structures (red), which can adopt either parallel or anti-parallel conformations with potentially distinct functions.

Figure 6: Cell Cycle Analysis

Figure 5: Relative cell count

Future Research Future PK/PD studies will be conducted to further characterize these findings

Funding This work was supported by the National Institutes of Health under grant CA259570 to J.C.S. and R01NS115507 to H.Z . Additionally, M.Z. was supported by 22-1041992-01-DPBACC from the American Cancer Society. This research also was supported by the National Cancer Institute of the National Institutes of Health under award number P30CA023074 through the University of Arizona Comprehensive Cancer Center shared resources, and the R Ken Coit endowment at the University of Arizona (to H.Z.).


53


Agenda Speakers Poster Session


Turn static files into dynamic content formats.

Create a flipbook
ACDD 2026 Extended Program by UAZCancerCenter - Issuu